Arachidonate 5-lipoxygenase

1545:-eicosatrienoic acid (5-HETrE), 5-oxo-6,8,11-eicosatrienoic acid (5-oxo-ETrE), LTA3, and LTC3; since LTA3 inhibits LTA hydrolase, mead acid metabolizing cells produce relatively little LTB3 and are blocked from metabolizing arachidonic acid to LTB4. On the other hand, 5-oxo-ETrE is almost as potent as 5-oxo-ETE as an eosinophil chemotactic factor and may thereby contribute to the development of physiological and pathological allergic responses. Presumably, the same metabolic pathways that follow ALOX5 in metabolizing arachidonic acid to the 4-series metabolites likewise act on mead acid to form these products. 1676:. This may be a reflection of the array of metabolites made by the Alox5 enzyme some of which possess opposing activities like the pro-inflammatory chemotactic factors and the anti-inflammatory specialized pro-resolving mediators. Alox5 and presumably human ALOX5 functions may vary widely depending on: the agents stimulating their activity; the types of metabolites that they form; the specific tissues responding to these metabolites; the times (e.g. early versus delayed) at which observations are made; and very likely various other factors. 1581:-eiosapentaenoic acid), to 5-hydroperoxy-eicosapentaenoic acid which is then converted to 5-series products that are structurally analogous to their arachidonic acid counterparts viz., 5-hydroxy-eicosapentaenoic acid (5-HEPE), 5-oxo-eiocosapentaenoic acid (5-oxo-HEPE), LTB5, LTC5, LTD5, and LTE5. Presumably, the same metabolic pathways that follow ALOX5 in metabolizing arachidonic acid to the 4-series metabolites likewise act on EPA to form these 5-series products. ALOX5 also cooperates with other lipoxygenase, 2145:. Zyleuton and zileuton CR cause elevations in liver enzymes in 2% of patients; the two drugs are therefore contraindicated in patients with active liver disease or persistent hepatic enzyme elevations greater than three times the upper limit of normal. Hepatic function should be assessed prior to initiating either of these drugs, monthly for the first 3 months, every 2–3 months for the remainder of the first year, and periodically thereafter; zileuton also has a rather unfavorable pharmacological profile (see 2283:

suppress inflammation depending on the relative roles these opposing metabolites have in regulating the particular type of reaction examined. Furthermore, the ALOX5-related tissue reactions studied to date are influenced by multiple genetic, environmental, and developmental variables that may influence the consequences of abnormalities in the expression or function of ALOX5. Consequently, abnormalities in the

795:. The physiological and/or pathological consequences of this slicing has yet to be defined. In one study, however, human brain tumors were shown to express three mRNA splice variants (2.7, 3.1, and 6.4 kb) in addition to the full 8.6 lb species; the abundance of the variants correlated with the malignancy of these tumors suggesting that they may play a role in the development of these tumors. 7451: 1310: 4681:

Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, Brockow K, Campo P, Celik G, Cernadas J, Cortellini G, Gomes E, Niżankowska-Mogilnicka E, Romano A, Szczeklik A, Testi S, Torres MJ, Wöhrl S, Makowska J (2013). "Classification and practical approach to the diagnosis and management

1264:

or scaffold, thereby averting the enzyme's inactivation to promote its metabolic activity; depending on circumstance such as the presence of phospholipids and levels of ambient Ca, this binding also alters the relative levels of hydroperoxy versus epoxide (see arachidonic acid section below) products

2128:

Zileuton is approved in the US for the prophylaxis and chronic treatment of allergic asthma; it is also used to treat chronic non-allergic reactions such as NSAID-induced non-allergic lung, nose, and conjunctiva reactions as well as exercise-induced asthma. Zileuton has shown some beneficial effects

1600:

5-HEPE, 5-oxo-HEPE, LTB5, LTC5, LTD5, and LTE5 are generally less potent in stimulating cells and tissues than their arachidonic acid-derived counterparts; since their production is associated with reduced production of their arachidonic acid-derived counterparts, they may indirectly serve to reduce

1438:

and may thereby contribute to eosinophil-based allergic reactions and diseases. These metabolites may also contribute to the progression of certain cancers such as those of the prostate, breast, lung, ovary, and pancreas. ALOX5 may be overexpressed in some of these cancers; 5-Oxo-ETE and to a lesser

2261:

To date, however, neither LTB4 synthesis inhibitors (i.e. blockers of ALOX5 or LTA4 hydrolase) nor inhibitors of LTB4 receptors (BLT1 and BLT2) have turned out to be effective anti-inflammatory drugs. Furthermore, blockers of LTC4, LTD4, and LTE4 synthesis (i.e. ALOX5 inhibitors) as well as of LTC4

2282:

ALOX5 contributes to the formation of PUFA metabolites that may promote (e.g. the leukotrienes, 5-oxo-ETE) but also to metabolites that inhibit (i.e. lipoxins, resolvins) diseases. Consequently, a given abnormality in the expression or activity of ALOX5 due to variations in its gene may promote or

2169:

serum liver enzyme elevations occurred in up to 10% of patients on flavocoxid therapy although elevations above 3 times the upper limit of normal occurred in only 1-2% of recipients. Since its release, however, there have been several reports of clinically apparent acute liver injury attributed to

1493:

LxA4 and LxB4 are members of the specialized pro-resolving mediators class of polyunsaturated fatty acid metabolites. They form later than the ALOX5-derived chemotactic factors in the inflammatory response and are thought to limit or resolve these responses by, for example, inhibiting the entry of

2165:. It inhibits COX-1, COX-2, and ALOX5 in vitro and in animal models. Flavocoxid has been approved for use as a medical food in the United States since 2004 and is available by prescription for use in chronic osteoarthritis in tablets of 500 mg under the commercial name Limbrel. However, in 1771:

cells that were directly implanted into their lungs; this result differs from many in vitro studies which implicated human ALOX5 along with certain of its metabolites with promoting cancer cell growth in that it finds that mouse Alox5 and, perhaps, certain of its metabolites inhibit cancer cell

1187:

on leukocytes. Rises in cytosolic Ca, ALOX5's movement to membranes, and ALOX5's interaction with FLAP are critical to the physiological activation of the enzyme. Serine 271 and 663 phosphorylations do not appear to alter ALOX5's activity. Serine 523 phosphorylation (which is conducted by PKA)

1117:

Sub-human mammalian Alox5 enzymes like those in rodents appear to have, at least in general, similar structures, distributions, activities, and functions as human ALOX5. Hence, model Alox5 studies in rodents appear to be valuable for defining the function of ALOX5 in humans (see

1265:

made by ALOX5. The binding of ALOX5 to membranes as well as its interaction with FLAP likewise cause the enzyme to alter its relative levels of hydroperoxy versus epoxide production, in these cases favoring the production of the epoxide products. The presence of certain

1757:(SPMs), at least in certain rodent inflammation-based model systems. These genetic studies allow that ALOX5 along with the chemotactic factors and SPMs that they contribute to making may play similar opposing pro-inflammatory and anti-inflammatory functions in humans. 1182:

thereby becomes suited for high metabolic activity. These events, along with rises in cytosolic Ca levels, which promote the translocation of ALOX5 form the cytoplasm and nucleoplasm to the cited membranes, are induced by cell stimulation such as that caused by

2226:, one of the bioactive boswellic acids found in Boswellia serrata (Indian Frankincense) has been found to inhibit 5-lipoxygenase. Boswellia reduces brain edema in patients irradiated for brain tumor and it's believed to be due to 5-lipoxygenase inhibition. 775:

Aberrant expression of LOX5 is seen in various types of human cancer tumors in vivo as well as in various types of human cancer cell lines in vitro; these tumors and cell lines include those of the pancreas, prostate and colon. ALOX5 products, particularly

2249:

which contributes to mediating the actions of LTC4, LTD4, and LTE4. These drugs are in common use as prophylaxis and chronic treatment of allergic and non-allergic asthma and rhinitis diseases and also may be useful for treating acquired childhood

1986:

It may also contribute to hypersensitivity responses of the respiratory system to cold air and possibly even alcohol beverages. These pathological responses likely involve the same ALOX5-formed metabolites as those promoting allergic reactions.

1529:-eicosatrienoic acid) is identical to AA except that has a single rather than double bond between its 14 and 15 carbon. ALOX5 metabolizes mead acid to 3-series (i.e. containing 3 double bonds) analogs of its 4-series AA metabolites viz., 5( 1306:

ALOX5 metabolizes various omega-3 and omega-6 PUFA to a wide range of products with varying and sometimes opposing biological activities. A list of these substrates along with their principal metabolites and metabolite activities follows.

1780:

to the sites of implantation. This striking difference between human in vitro and mouse in vivo studies may reflect species differences, in vitro versus in vivo differences, or cancer cell type differences in the function of ALOX5/Alox5.

1430:, i.e. they recruit and further activate circulating blood neutrophils and monocytes to sites of microbial invasion, tissue injury, and foreign bodies. When produced in excess, however, they may contribute to a wide range of pathological 2315:. These variants are associated with reduced levels of ALOX5 as well as reduced production of LTC4 in their eosinophils. These data suggest that ALOX5 may contribute to dampening the severity of asthma, possibly by metabolizing PUFA to 3063:

O'Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, Clay CE, High K, Chen YQ, Willingham MC, Smitherman PK, Kute TE, Rao A, Cramer SD, Morrow CS (October 2005). "5-Oxo-ETE analogs and the proliferation of cancer cells".

2343:) have been associated with the presence of asthma in single population studies. These studies suggest genetic variants may play a role, albeit a relatively minor one, in the overall susceptibility to allergic asthma. 2421:-1708 G>A is associated with NSAID-induced asthma in Korean patients and three SNP ALOX5 variants, rs4948672, rs1565096, and rs7894352, are associated with NSAID-induced cutaneous reactions in Spanish patients. 1473:

by contracting these airways and promoting in these airways inflammation, micro-vascular permeability, and mucus secretion; they likewise contribute to various allergic and non-allergic reactions involving

2697:

Ahmad S, Thulasingam M, Palombo I, Daley DO, Johnson KA, Morgenstern R, Haeggström JZ, Rinaldo-Matthis A (2015). "Trimeric microsomal glutathione transferase 2 displays one third of the sites reactivity".

2433:

gene promoter in 470 subjects (non-Hispanic whites, 55.1%; Hispanics, 29.6%; Asian or Pacific Islander, 7.7&; African Americans, 5.3%, and others, 2.3%) were positively associated with the severity of

2358:(NSAID) can cause NSAID-exacerbated diseases (N-ERD). These have been recently classified into 5 groups 3 of which are not caused by a classical immune mechanism and are relevant to the function of ALOX5: 3909:

Oussalah A, Mayorga C, Blanca M, Barbaud A, Nakonechna A, Cernadas J, Gotua M, Brockow K, Caubet JC, Bircher A, Atanaskovic M, Demoly P, K Tanno L, Terreehorst I, Laguna JJ, Romano A, Guéant JL (2016).

1229:) in particular mediates many instances of stimulus-induced release of PUFA in inflammatory cells. For example, chemotactic factors stimulate human neutrophils to raise cytosolic Ca which triggers cPLA 684:. A novel Sp1-binding site occurs close to the major transcription start site (position – 65); a GC-rich core region including the Sp1/Egr-1 sites may be critical for basal 5-LO promoter activity. 1672:

gene have given seemingly paradoxical results. In mice, for example, Alox5 overexpression may decrease the damage caused by some types yet increase the damage caused by other types of invasive

5899: 2438:, as judged by carotid intima–media thickness measurements. Variant alleles involved deletions (one or two) or additions (one, two, or three) of Sp1 motifs to the five tandem motifs allele. 3493: 1772:

growth. Studies in this model suggest that Alox5, acting through one or more of its metabolites, reduces growth and progression of the Lewis carcinoma by recruiting cancer-inhibiting CD4+

1439:

extent 5-HETE stimulate human cell lines derived from these cancers to proliferate; and the pharmacological inhibition of ALOX5 in these human cell lines causes them to die by entering

1494:

circulating leukocytes into inflamed tissues, inhibiting the pro-inflammatory action of the leukocytes, promoting leukocytes to exit from inflammatory sites, and stimulating leukocyte

5694: 784:, promote the proliferation of these ALOX5 aberrantly expressing tumor cell lines suggesting that ALOX5 acts as a pro-malignancy factor for them and by extension their parent tumors. 2270:

as single drug therapy for persistent asthma, particularly in patients with airway obstruction. As a second drug added to corticosteroids, leukotriene inhibitors appear inferior to

4888:

Ishii S, Noguchi M, Miyano M, Matsumoto T, Noma M (1992). "Mutagenesis studies on the amino acid residues involved in the iron-binding and the activity of human 5-lipoxygenase".

2129:

in clinical trials for the treatment of rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Zileuton is currently undergoing a phase II study for the treatment of

3539:

Santos PC, Santos DA, Ribeiro LS, Fagundes CT, de Paula TP, Avila TV, Baltazar Lde M, Madeira MM, Cruz Rde C, Dias AC, Machado FS, Teixeira MM, Cisalpino PS, Souza DG (2013).

1256:

Other factors are known to regulate ALOX5 activity in vitro but have not been fully integrated into its physiological activation during cell stimulation. ALOX5 binds with the

5391:

VanderNoot VA, Fitzpatrick FA (1995). "Competitive binding assay of src homology domain 3 interactions between 5-lipoxygenase and growth factor receptor binding protein 2".

5490:

Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library".

4049:

Barros R, Moreira A, Padrão P, Teixeira VH, Carvalho P, Delgado L, Lopes C, Severo M, Moreira P (2015). "Dietary patterns and asthma prevalence, incidence and control".

2229:

While only one ALOX5-inhibiting drug has proven useful for treating human diseases, other drugs that act down-stream in the ALOX5-initiated pathway are in clinical use.

546: 1396:) by cell surface-attached gamma-glutamyltransferase and dipeptidase peptidase enzymes. In another pathway, ALOX5 may act in series with a second lipoxygenase enzyme, 769: 5577: 2584:

Anwar Y, Sabir JS, Qureshi MI, Saini KS (2014). "5-lipoxygenase: a promising drug target against inflammatory diseases-biochemical and pharmacological regulation".

1188:

totally inactivates the enzyme and prevents its nuclear localization; stimuli which cause cells to activate PKA can thereby block production of ALOX5 metabolites.

6591: 5892: 2916:"Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid" 565: 1749:

injury. These studies indicate that Alox5 can serve a protective function presumably by generating metabolites such as chemotactic factors that mobilize the

5687: 4441:"Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial" 1753:

system. However, the suppression of inflammation appears also to be a function of Alox5, presumably by contributing to the production of anti-inflammatory

2402:

NSAIDs-induced urticaria/angioedema (NIUA) (i.e. wheals and/or angioedema symptoms occurring shortly after NSAID ingestion in patients with no history of

1731:-null mice exhibit a worsened inflammatory component, failure to resolve inflammation-related responses, and decreased survival in experimental models of 4293:

Albert D, Zündorf I, Dingermann T, Müller WE, Steinhilber D, Werz O (Dec 2002). "Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase".

852:

within its C2-like domain; this domain, by analogy to other PLAT domain-bearing proteins, may serve as a mobile lid over ALOX5's substrate-binding site

5885: 4853:

Hammarberg T, Reddy KV, Persson B, Rådmark O (2002). "Calcium Binding to 5-Lipoxygenase". In Honn KV, Marnett LJ, Nigam S, Dennis E, Serhan C (eds.).

1237:α), to move from its normal residence in the cytosol to cellular membranes. This chemotactic factor stimulation concurrently causes the activation of 4488:

Kar M, Altıntoprak N, Muluk NB, Ulusoy S, Bafaqeeh SA, Cingi C (2016). "Antileukotrienes in adenotonsillar hypertrophy: a review of the literature".

6995: 6961: 5236:"5-Lipoxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins" 2783:

Wykle RL, Wijkander J, Nixon AB, Daniel LW, O'Flaherty JT (1996). "Activation of 85 kDa PLA2 by Eicosanoids in Human Neutrophils and Eosinophils".

628:

as well as a wide range of other biologically active products. ALOX5 is a current target for pharmaceutical intervention in a number of diseases.

1958: 4328:

Blazevic T, Schaible AM, Weinhäupl K, Schachner D, Nikels F, Weinigel C, Barz D, Atanasov AG, Pergola C, Werz O, Dirsch VM, Heiss EH (Mar 2014).

3767:"Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment" 5680: 4919:"Evaluation of the role of conserved His and Met residues among lipoxygenases by site-directed mutagenesis of recombinant human 5-lipoxygenase" 7496: 4870: 3148:

Ding XZ, Tong WG, Adrian TE (2003). "Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer".

2800: 2446: 1996: 3344:

Maaløe T, Schmidt EB, Svensson M, Aardestrup IV, Christensen JH (Jul 2011). "The effect of n-3 polyunsaturated fatty acids on leukotriene B

2355: 1854:-HETE, which serve to attract and otherwise activate inflammation-inducing cells such as circulating leukocytes and tissue macrophages and 5298:

Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides".

2636:

Rådmark O, Werz O, Steinhilber D, Samuelsson B (2015). "5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease".

2311:

variants for this five repeat promoter region in a study of 624 asthmatic children in Ankara, Turkey were much more likely to have severe

1711:

gene knockout mice exhibited a decrease in the number of neutrophils and an increase in the number of bacteria that accumulated in their

7089: 6135: 6125: 5570: 2316: 1754: 1657: 1646: 1602: 1594: 1499: 1405: 2335:), or are the cellular receptors responsible for mediating the cellular responses to the down-stream ALOX products LTC4 and LTD4 (i.e. 5866: 5537: 3661:

Canavaci AM, Sorgi CA, Martins VP, Morais FR, de Sousa ÉV, Trindade BC, Cunha FQ, Rossi MA, Aronoff DM, Faccioli LH, Nomizo A (2014).

2255: 1345: 5181:

Janssen-Timmen U, Vickers PJ, Wittig U, Lehmann WD, Stark HJ, Fusenig NE, Rosenbach T, Rådmark O, Samuelsson B, Habenicht AJ (1995).

7170: 5822: 2324: 1408:). GPXs, 5-HEDH, LTA4H, LTC4S, ABCC1, and cell surface peptidases may act similarly on the ALOX5-derived metabolites of other PUFA. 1357: 1175: 558: 3608:

Fahel JS, de Souza MB, Gomes MT, Corsetti PP, Carvalho NB, Marinho FA, de Almeida LA, Caliari MV, Machado FS, Oliveira SC (2015).

1918:

LTC4, LTD4, and LTE4 which promote vascular permeability, contract airways smooth muscle, and otherwise perturb these tissues and

6929: 6435: 6372: 6199: 6120: 2246: 2177: 1943: 1660:

that contribute to the resolution of inflammation, promote tissue healing, and reduce the perception of inflammation-based pain.

1260:-binding protein, coactin-like protein. Based on in vitro studies, this protein binding serves to stabilize ALOX5 by acting as a 1238: 1139: 6769: 6115: 5972: 5146:

Jakobsson PJ, Shaskin P, Larsson P, Feltenmark S, Odlander B, Aguilar-Santelises M, Jondal M, Biberfeld P, Claesson HE (1995).

3814:

Rossi AG, O'Flaherty JT (1991). "Bioactions of 5-hydroxyicosatetraenoate and its interaction with platelet-activating factor".

509: 5457:"Contrasting effects of proinflammatory and T-helper lymphocyte subset-2 cytokines on the 5-lipoxygenase pathway in monocytes" 2204:, is also described as selective ALOX5 inhibitor effective in a range of cell-free and cell-based model systems. In addition, 1922:

LTB4 and possibly 5-oxo-ETE which are chemotactic factors for, and activators of, the cell type promoting such reactions, the

6687: 6659: 6530: 6185: 6130: 5563: 2410: 2320: 1415: 1353: 777: 485: 7326: 2876:

Romano M, Cianci E, Simiele F, Recchiuti A (2015). "Lipoxins and aspirin-triggered lipoxins in resolution of inflammation".

1814:

however, ALOX5 also contributes to the development and progression of excessive and chronic inflammatory responses such as:

5543: 5422:"Rapid import of cytosolic 5-lipoxygenase into the nucleus of neutrophils after in vivo recruitment and in vitro adherence" 4330:"Indirubin-3'-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration" 3912:"Genetic variants associated with drugs-induced immediate hypersensitivity reactions: a PRISMA-compliant systematic review" 7079: 5845: 5329:"5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes" 1699: 7441: 4232: 7055: 7041: 6988: 6954: 6669: 6631: 5790: 3302:"BLT2 is a pro-tumorigenic mediator during cancer progression and a therapeutic target for anti-cancer drug development" 2001:

The tissue, animal model, and animal and human genetic studies cited above implicate ALOX5 in a wide range of diseases:

1862:

lipoxin and resolvin subfamily of SPMs which tend to inhibit these cells as well as the overall inflammatory responses.

1487: 1253:

s to release PUFA esterified to membrane phospholipids to FLAP which then presents them to ALOX5 for their metabolism.

1114:. To varying extents, the other PUFA substrates of ALOX5 follow similar metabolic pathways to form analogous products. 7094: 7050: 1732: 1419: 1361: 781: 978:), or, alternatively, further metabolized by ALOX5's epoxidase (also termed LTA4 synthase) activity which converts 5 866:-rich region (residues 566–577), sometimes termed a SH3-binding domain, which promotes its binding to proteins with 6914: 2029: 1931: 1828: 1601:

the pro-inflammatory and pro-allergic activities of their arachidonic acid-derived counterparts. RvE1 and ReV2 are

1364:(5-oxo-ETE). Alternatively, the intrinsic activity of ALOX5 may convert 5-HpETE to its 5,6 epoxide, leukotriene A4 1192: 7311: 1486:. Certain of these peptide-leukotrienes have been shown to promote the growth of cultured human breast cancer and 503: 7491: 7427: 7414: 7401: 7388: 7375: 7362: 7349: 7128: 7109: 7064: 7021: 6096: 5953: 5778: 1444: 1103: 1059: 875: 644:(kb) on chromosome 10 (all other human lipoxygenases are clustered together on chromosome 17), is composed of 14 7321: 1348:) which is then rapidly converted to physiologically and pathologically important products. Ubiquitous cellular 1249:

isoforms using other kinases which phosphorylate them on different serine residues). These two events allow cPLA

7275: 7218: 7012: 6860: 6828: 6707: 5850: 5833: 5785: 5672: 5530: 2332: 2304: 2271: 2142: 2121:

However, clinical use of drugs that inhibit ALOX5 to treat any of these diseases has been successful with only

1373: 1015: 677: 490: 398: 5651: 3765:

Poczobutt JM, Nguyen TT, Hanson D, Li H, Sippel TR, Weiser-Evans MC, Gijon M, Murphy RC, Nemenoff RA (2016).

1451:

receptors have also been shown to promote the growth of various types of human cancer cell lines in culture.

7223: 6981: 6796: 6606: 5939: 5922: 5840: 1715:. On the other hand, ALOX5 gene knockout mice demonstrate an enhanced resistance and lessened pathology to 837:

which promotes its binding to ligand substrates, Ca, cellular phospholipid membranes, Coactin-like protein (

6850: 5555: 1685:

mice are more susceptible to the development and pathological complications of experimental infection with

570: 6786: 5804: 3951:

O'Flaherty JT, Kuroki M, Nixon AB, Wijkander J, Yee E, Lee SL, Smitherman PK, Wykle RL, Daniel LW (1996).

2039: 1423: 1349: 951: 856: 478: 7244: 7163: 6649: 6573: 5928: 5797: 5741: 5594: 2059: 1875: 1687: 1656:(i.e. RvD1, RvD2, RvD3, RvD4, RvD5, RvD6, AT-RVD1, AT-RVD2, AT-RVD3, AT-RVD4, AT-RVD5, and AT-RVD6) are 1558: 1431: 1167: 7316: 5526: 5327:

Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, Heibein JA, Charleson S, Singer II (1993).

3251:

Bäck M, Powell WS, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE (2014).

5060:"Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187" 7486: 7471: 7084: 7074: 6909: 6555: 6140: 6003: 5977: 5661: 5194: 5106: 5018: 4965: 4189:

Cingi C, Muluk NB, Ipci K, Şahin E (2015). "Antileukotrienes in upper airway inflammatory diseases".

2477: 2193: 2019: 1963: 1818: 1768: 1693: 1618: 792: 621: 506: 5269:

Shaw KJ, Ng C, Kovacs BW (1994). "Cyclooxygenase gene expression in human endometrium and decidua".

430: 7476: 7280: 6601: 5549: 4761: 4743: 3953:"5-Oxo-eicosatetraenoate is a broadly active, eosinophil-selective stimulus for human granulocytes" 2429:

Bearers of two variations in the predominant five tandem repeat Sp1 binding motif (GGGCCGG) of the

2363: 2296: 2263: 2242: 2197: 1470: 1275: 1261: 1197: 410: 6744: 3101:"Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling" 7213: 7137: 7099: 6724: 5914: 5646: 4707: 4513: 4470: 4267: 4214: 4074: 3982: 3839: 3541:"The pivotal role of 5-lipoxygenase-derived LTB4 in controlling pulmonary paracoccidioidomycosis" 3521: 3471: 3230: 3173: 2034: 1947: 1833: 1554: 1321: 70: 6578: 6347: 6327: 6322: 6312: 6292: 6277: 6267: 6076: 6046: 6021: 3099:

Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martínez A, Mulshine JL (February 1996).

1130:

ALOX5 exists primarily in the cytoplasm and nucleoplasm of cells. Upon cell stimulation, ALOX5:

676:. Five of the 8 GC boxes are arranged in tandem and are recognized by the transcription factors 6754: 6697: 6352: 6287: 6282: 6272: 6171: 6166: 6161: 6086: 6066: 6041: 6031: 6026: 6016: 6011: 5993: 2362:

NSAIDs-exacerbated respiratory disease (NERD), i.e. symptoms of bronchial airways obstruction,

6611: 6563: 6535: 6425: 6420: 6337: 6307: 6262: 6257: 6252: 6071: 6061: 6056: 6051: 5507: 5478: 5443: 5408: 5379: 5358: 5315: 5286: 5257: 5222: 5169: 5134: 5081: 5046: 4993: 4940: 4905: 4876: 4866: 4841: 4802: 4781:"Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis" 4699: 4663: 4614: 4562: 4505: 4462: 4439:

Kirste S, Treier M, Wehrle SJ, Becker G, Abdel-Tawab M, Gerbeth K, et al. (August 2011).

4400: 4359: 4310: 4206: 4171: 4123: 4066: 4031: 3974: 3933: 3888: 3831: 3796: 3747: 3698: 3643: 3572: 3513: 3463: 3421: 3392:"The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution" 3369: 3323: 3282: 3222: 3165: 3130: 3081: 3045: 2989: 2945: 2893: 2855: 2806: 2796: 2765: 2715: 2653: 2601: 2553: 2505: 2407: 2403: 2395: 2200:

in inhibiting ALOX5. Indirubin-3'-monoxime, a derivative of the naturally occurring alkaloid,

1741: 1723: 1490:

cell lines thereby suggesting that ALOX5 may contribute to the progression of these diseases.

1434:(5-HETE and LTB4). 5-Oxo-ETE is a particularly potent chemotactic factor for and activator of 673: 497: 48: 6749: 6520: 6362: 6332: 6081: 4002:"Lipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic Targets" 3352:

production from stimulated neutrophil granulocytes in patients with chronic kidney disease".

1469:, certain non-allergic hypersensitivity airways reactions, and other lung diseases involving 466: 7481: 7259: 7254: 7228: 7156: 6973: 6924: 6734: 6682: 6644: 6616: 6515: 6505: 6481: 6297: 5729: 5707: 5613: 5499: 5468: 5433: 5400: 5348: 5340: 5307: 5278: 5247: 5212: 5202: 5159: 5124: 5114: 5071: 5036: 5026: 4983: 4973: 4930: 4897: 4858: 4857:. Advances in Experimental Medicine and Biology. Vol. 507. Springer. pp. 117–121. 4833: 4792: 4691: 4653: 4645: 4604: 4596: 4552: 4544: 4497: 4452: 4390: 4349: 4341: 4302: 4198: 4161: 4113: 4105: 4058: 4021: 4013: 3964: 3923: 3911: 3878: 3870: 3823: 3786: 3778: 3737: 3729: 3688: 3678: 3633: 3625: 3562: 3552: 3505: 3455: 3411: 3403: 3361: 3313: 3272: 3264: 3212: 3204: 3157: 3120: 3112: 3073: 3035: 3027: 2979: 2935: 2927: 2885: 2845: 2837: 2788: 2757: 2707: 2645: 2593: 2543: 2495: 2485: 2367: 1777: 1717: 1325: 1226: 1206: 1163: 1151: 1147: 883: 812: 761: 4837: 3446:

Qu Q, Xuan W, Fan GH (2015). "Roles of resolvins in the resolution of acute inflammation".

1205:, in order to form biologically active products. This is accomplished by a large family of 442: 7306: 7290: 7203: 5736: 5586: 4725: 3859:"Specialized pro-resolving mediators: endogenous regulators of infection and inflammation" 2435: 2024: 1855: 1823: 1795: 1750: 1586: 749: 701: 403: 4421:

Antiödematöse Wirkung von Boswellia serrata auf das Strahlentherapie-assoziierte Hirnödem

5198: 5110: 5022: 4969: 4426:

Anti-edematous effect of Boswellia serrata on radiation therapy – associated brain edema

4379:"5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy" 3217: 3192: 2481: 7455: 7344: 7285: 7004: 6934: 6454: 6407: 6399: 6391: 6234: 6226: 6218: 6148: 5985: 5911: 5759: 5590: 5353: 5328: 5164: 5147: 4855:

Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 5

4658: 4633: 4609: 4584: 4557: 4532: 4354: 4329: 4118: 4093: 4026: 4001: 3883: 3858: 3791: 3766: 3742: 3717: 3693: 3662: 3638: 3609: 3567: 3540: 3416: 3391: 3318: 3301: 3277: 3252: 3040: 3015: 2940: 2915: 2850: 2825: 2684: 2671: 2387: 2379: 2267: 2221: 2166: 2134: 2071: 1969: 1888: 1582: 1479: 1266: 1019: 950:-HpETE intermediate may then be released by the enzyme and rapidly reduced by cellular 834: 764:

express low levels of ALOX5. Up-regulation of ALOX5 may occur during the maturation of

729: 541: 5503: 5370:

Mancini JA, Li C, Vickers PJ (1993). "5-Lipoxygenase activity in the human pancreas".

5252: 5235: 5129: 5094: 5076: 5059: 5041: 5006: 4935: 4918: 4306: 3125: 3100: 2597: 2500: 2465: 1102:-eicosatetraenoic acid). The Glu and Gly residues of LTC4 may be removed step-wise by 521: 67: 7465: 7249: 7208: 6904: 5311: 5282: 5217: 5182: 5148:"Studies on the regulation and localization of 5-lipoxygenase in human B-lymphocytes" 4988: 4953: 4901: 2130: 1773: 1682: 1381: 1055: 757: 657: 516: 4711: 4517: 4474: 4218: 4078: 3986: 3525: 3475: 3177: 2746:"Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease" 1798:

by contributing to the mounting inflammatory responses to a wide range of diseases:

1245:α by phosphorylating it on ser-505 (other cell types may activate this or other cPLA 787:

Studies with cultured human cells have found that there are a large number of ALOX5

7198: 7031: 6739: 6525: 5877: 5656: 3843: 3234: 2048: 2010: 1840: 1807: 1736: 1202: 1119: 891: 733: 693: 617: 4262: 3031: 2787:. Advances in Experimental Medicine and Biology. Vol. 416. pp. 327–331. 882:

The enzyme possesses two catalytic activities as illustrated by its metabolism of

4862: 4779:

Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M (2004).

4649: 4634:"DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation" 4548: 3557: 3509: 3077: 2931: 2889: 2792: 2711: 2649: 2180:, and atherosclerosis (NCT00404313, NCT00418613, and NCT00421278, respectively). 7422: 7357: 7193: 6919: 6568: 6357: 6302: 5908: 5814: 5641: 5625: 5620: 3733: 3590: 3365: 2394:

responses occurring shortly after NSAID ingestion in patients with a history of

2251: 2234: 2230: 1066:), which bind the sulfur of cysteine's thio (i.e. SH) residue in the tripeptide 887: 849: 745: 625: 525: 7450: 4600: 4109: 3969: 3952: 3407: 2984: 2967: 2470:

Proceedings of the National Academy of Sciences of the United States of America

2176:(MK-0633) has completed a Phase II clinical trial for the treatment of asthma, 1850:

potent chemotactic factor, LTB4, and possibly also weaker chemotactic factor, 5

7118: 6876: 6813: 6550: 6342: 6317: 5751: 5711: 5703: 4501: 4240: 4202: 4017: 3208: 2841: 2391: 2371: 2308: 2238: 2188: 2153: 2117:

the progression of certain cancers such as those of the prostate and pancreas.

2105: 1979: 1974: 1951: 1923: 1712: 1435: 1427: 1184: 867: 831: 824: 808: 753: 721: 709: 705: 653: 17: 4824:

Rådmark OP (2000). "The molecular biology and regulation of 5-lipoxygenase".

3782: 3253:"Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7" 7396: 7370: 7008: 6729: 6654: 6545: 6510: 5438: 5421: 5207: 4978: 2201: 2110: 1514: 1495: 1483: 1440: 1309: 1143: 1067: 765: 725: 641: 86: 63: 5404: 5344: 5005:

Matsumoto T, Funk CD, Rådmark O, Höög JO, Jörnvall H, Samuelsson B (1988).

4880: 4845: 4806: 4703: 4667: 4618: 4566: 4509: 4466: 4404: 4363: 4314: 4210: 4175: 4127: 4070: 4035: 3937: 3892: 3800: 3751: 3702: 3647: 3576: 3517: 3494:"n-3 Fatty acid supplementation and proresolving mediators of inflammation" 3467: 3425: 3373: 3327: 3286: 3226: 3169: 3085: 3049: 2993: 2949: 2897: 2859: 2769: 2719: 2657: 2605: 2557: 2490: 1597:

for further details on this metabolism) viz., resolvin E1 (RvE1) and RvE2.

5511: 5482: 5447: 5412: 5383: 5362: 5319: 5290: 5261: 5226: 5183:"Expression of 5-lipoxygenase in differentiating human skin keratinocytes" 5173: 5138: 5119: 5085: 5050: 4997: 4944: 4909: 4537:

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

4395: 4378: 3978: 3835: 3683: 3134: 3066:

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

2920:

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

2810: 2638:

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

2509: 2256:

Acquired non-inflammatory myopathy § Diet and Trauma Induced Myopathy

2184:

has completed phase II studies for the treatment of asthma (NCT00723021).

2149:). Given these deficiencies, other drugs targeting ALOX5 are under study. 454: 371: 6881: 6845: 6759: 6692: 6583: 6540: 6247: 6036: 5608: 5031: 4797: 4780: 4428:] (Ph.D. thesis) (in German). Breisgau, Germany: University Freiburg. 4345: 3629: 2213: 2209: 2205: 2162: 2158: 2157:

is a proprietary blend of purified plant derived bioflavonoids including

2146: 2138: 2122: 2066: 2006: 1883: 1803: 1673: 1653: 1590: 1475: 1071: 737: 717: 713: 665: 360: 5473: 5456: 5093:

Dixon RA, Jones RE, Diehl RE, Bennett CD, Kargman S, Rouzer CA (1988).

4457: 4440: 4166: 4149: 3874: 3827: 3459: 2548: 2531: 2351: 2340: 2336: 2055: 1907: 1871: 1605:

that contribute to the resolution of inflammation and other reactions.

1503: 1401: 1257: 1195:(PUFA) substrates, which commonly are bound in an ester linkage to the 1075: 983: 863: 804: 697: 669: 473: 190: 149: 6592: 4695: 4279: 4062: 3928: 3268: 3161: 3116: 2761: 2374:

occurring shortly after NSAID ingestion in patients with a history of

914:-eicosatetraenoic acid) at carbon 5 of its 1,4 diene group (i.e. its 5 7409: 7179: 7059: 7045: 6818: 6621: 6475: 5715: 2375: 2312: 2133:(mild-to-moderate inflammatory facial acne) and a phase I study (see 2086: 2076: 1903: 1893: 1746: 1614: 1466: 1397: 1135: 975: 741: 661: 649: 606: 553: 449: 437: 425: 338: 108: 74: 2745: 2464:

Funk CD, Hoshiko S, Matsumoto T, Rdmark O, Samuelsson B (Apr 1989).

1930:-HETE, also act synergistically with another pro-allergic mediator, 208: 204: 5007:"Molecular cloning and amino acid sequence of human 5-lipoxygenase" 4150:"Recent advances in the search for novel 5-lipoxygenase inhibitors" 1846:

These dual functions probably reflect ALOX5's ability to form the:

7383: 5769: 5764: 4419: 1704: 1385: 1063: 842: 681: 859:(ATP) binding site; ATP is crucial for ALOX5's metabolic activity 2081: 1898: 1647:

Specialized pro-resolving mediators § DHA-derived resolvins

1595:

Specialized pro-resolving mediators § EPA-derived resolvins

1462: 1458: 1454: 1448: 1411: 1393: 1389: 1377: 1369: 1365: 1344:-eicosatetraenoic acid), to 5-hydroperoxyeicosatetraenoic acid ( 1155: 1111: 1107: 1011: 871: 838: 788: 645: 613: 602: 461: 7152: 6977: 5881: 5676: 5559: 3016:"The eosinophil chemoattractant 5-oxo-ETE and the OXE receptor" 1668:

Studies in model animal systems that delete or overexpress the

1174:

is able to accept substrate fatty acids presented to it by the

4682:

of hypersensitivity to nonsteroidal anti-inflammatory drugs".

4266:

for "The Effect of MK0633 in Patients With Chronic Asthma" at

816: 2700:

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

2125:

along with its controlled released preparation, Zileuton CR.

1443:. ALOX5 and its LTB4 metabolite as well as this metabolite's 1298:-glycerol increase the catalytic activity of ALOX5 in vitro. 1191:

In addition to its activation, ALOX5 must gain access to its

4954:"Characterization of the human 5-lipoxygenase gene promoter" 4239:. United States National Library of Medicine. Archived from 1368:, which is then either rapidly converted to leukotriene B4 ( 1284: 4000:

Schauberger E, Peinhaupt M, Cazares T, Lindsley AW (2016).

2323:

differences in the genes that promote ALOX5 activity (i.e.

2287:

gene may vary with the population and individuals studied.

1227:

Phospholipase A2 § Cytosolic phospholipases A2 (cPLA2)

7148: 4917:

Nguyen T, Falgueyret JP, Abramovitz M, Riendeau D (1991).

4585:"Genetics and pharmacogenetics of the leukotriene pathway" 2303:

gene commonly possess five GGGCCGG repeats which bind the

1589:

enzymes in serial metabolic pathways to metabolize EPA to

3667:

infection is attenuated in 5-lipoxygenase-deficient mice"

3610:"5-Lipoxygenase negatively regulates Th1 response during 1352:(GPXs) reduce 5-HpETE to 5-hydroxyeicosatetraenoic acid ( 1014:). LTA4 is then acted on by a separate, soluble enzyme, 6436: 6373: 6200: 5420:

Brock TG, McNish RW, Bailie MB, Peters-Golden M (1997).

4533:"Mammalian lipoxygenases and their biological relevance" 2785:

Platelet-Activating Factor and Related Lipid Mediators 2

2307:

and thereby increase the gene's transcription of ALOX5.

1870:

ALOX5 contributes to the development and progression of

620:

family of enzymes. It transforms essential fatty acids (

3354:

Prostaglandins, Leukotrienes, and Essential Fatty Acids

2009:, trauma, burns, and other forms of tissue injury (see 656:(kDa) ALOX5 protein consisting of 673 amino acids. The 6597:

Tooltip Arachidonate 5-lipoxygenase-activating protein

6186: 7439: 6770: 6670: 6632: 2093:

NSAID-induced acute non-allergic reactions such as:

1384:(LTC4S); LTC4 exits its cells of origin through the 1241:(MAPK) which in turn stimulates the activity of cPLA 7335: 7299: 7268: 7237: 7186: 7127: 7108: 7020: 6894: 6859: 6827: 6795: 6768: 6706: 6668: 6630: 6493: 6491: 6474: 6434: 6371: 6198: 6184: 6095: 5952: 5938: 5921: 5859: 5813: 5750: 5722: 5634: 5601: 3718:"Lipid mediators in the resolution of inflammation" 2466:"Characterization of the human 5-lipoxygenase gene" 1934:, to stimulate and otherwise activate eosinophils. 1645:-docosahexaenoic acid), to D series resolvins (see 1406:

Specialized pro-resolving mediators § Lipoxins

1158:, and/or a Ca/calmodulin-dependent protein kinase; 564: 552: 540: 535: 515: 496: 484: 472: 460: 448: 436: 424: 419: 409: 397: 392: 387: 305: 286: 262: 243: 5455:Nassar GM, Montero A, Fukunaga M, Badr KF (1997). 4762:"Reference SNP (refSNP) Cluster Report: rs7894352" 4744:"Reference SNP (refSNP) Cluster Report: rs1565096" 4726:"Reference SNP (refSNP) Cluster Report: rs4948672" 4154:Basic & Clinical Pharmacology & Toxicology 2536:Basic & Clinical Pharmacology & Toxicology 2386:NSAIDs-exacerbated cutaneous disease (NECD), i.e. 1302:Substrates, metabolites, and metabolite activities 6097: 5954: 2739: 2737: 2735: 2733: 2731: 2729: 1767:in the lung tumor volume and liver metastasis of 1465:contribute to allergic airways reactions such as 1178:(FLAP) which is embedded in these membranes; and 672:and thus resembles the gene promoters of typical 616:. Arachidonate 5-lipoxygenase is a member of the 609:(EC 1.13.11.34) that in humans is encoded by the 6861: 6829: 6708: 3300:Cho NK, Joo YC, Wei JD, Park JI, Kim JH (2013). 1078:to carbon 6 of LTA4 thereby forming LTC4 (i.e. 5 874:and may thereby link the enzyme's regulation to 770:granulocyte macrophage colony-stimulating factor 6797: 5940: 4578: 4576: 4143: 4141: 4139: 4137: 3904: 3902: 3487: 3485: 3441: 3439: 3437: 3435: 3385: 3383: 3246: 3244: 3009: 3007: 3005: 3003: 2968:"The role of leukotrienes in allergic diseases" 2961: 2959: 2909: 2907: 2871: 2869: 772:and then stimulated with physiological agents. 5095:"Cloning of the cDNA for human 5-lipoxygenase" 4589:The Journal of Allergy and Clinical Immunology 3716:Serhan CN, Chiang N, Dalli J, Levy BD (2015). 3339: 3337: 2631: 2629: 2627: 2625: 2623: 2621: 2619: 2617: 2615: 2579: 2577: 2575: 2573: 2571: 2569: 2567: 2525: 2523: 2521: 2519: 2147:Zileuton § Contraindications and warnings 7164: 6989: 5893: 5688: 5571: 2327:), metabolize the initial product of ALOX5, 5 8: 3193:"Survival regulation of leukemia stem cells" 1721:infection and, at least in its acute phase, 4952:Hoshiko S, Rådmark O, Samuelsson B (1990). 1794:Studies implicate ALOX5 in contributing to 1294:-glycerol but not 1-stearoyl-2-arachidonyl- 7171: 7157: 7149: 6996: 6982: 6974: 6930:5-HPETE (arachidonic acid 5-hydroperoxide) 6488: 6195: 5949: 5935: 5900: 5886: 5878: 5695: 5681: 5673: 5578: 5564: 5556: 5271:Prostaglandins Leukot. Essent. Fatty Acids 4490:European Archives of Oto-Rhino-Laryngology 4098:Annals of Allergy, Asthma & Immunology 3722:Cold Spring Harbor Perspectives in Biology 2532:"5-lipoxygenase mRNA and protein isoforms" 532: 82: 5529:at the U.S. National Library of Medicine 5472: 5437: 5352: 5251: 5216: 5206: 5163: 5128: 5118: 5075: 5040: 5030: 4987: 4977: 4934: 4796: 4657: 4608: 4556: 4456: 4394: 4353: 4165: 4117: 4025: 3968: 3927: 3882: 3790: 3741: 3692: 3682: 3637: 3566: 3556: 3415: 3317: 3276: 3216: 3124: 3039: 2983: 2939: 2849: 2547: 2499: 2489: 2016:chronic inflammatory conditions such as: 1649:for further details on this metabolism). 6444:Tooltip Cysteinyl leukotriene receptor E 6381:Tooltip Cysteinyl leukotriene receptor 2 6208:Tooltip Cysteinyl leukotriene receptor 1 4531:Kuhn H, Banthiya S, van Leyen K (2015). 4377:Bishayee K, Khuda-Bukhsh AR (Sep 2013). 2530:Ochs MJ, Suess B, Steinhilber D (2014). 1914:This activity reflects its formation of 1356:); 5-HETE may be further metabolized by 1162:moves to bind with phospholipids in the 7446: 4094:"Lipid mediators and allergic diseases" 2456: 2254:due to adenotonsillar hypertrophy (see 1959:aspirin-exacerbated respiratory disease 1120:Lipoxygenase § Mouse lipoxygenases 1106:and a dipeptidase to form sequentially 692:Cells primarily involved in regulating 6191:Tooltip Cysteinyl leukotriene receptor 4838:10.1164/ajrccm.161.supplement_1.ltta-3 1926:. 5-Oxo-ETE and, to a lesser extent, 5 1617:to metabolize the omega 3 fatty acid, 768:and in human neutrophils treated with 384: 29: 3591:"Alox5 – arachidonate 5-lipoxygenase" 3390:Serhan CN, Chiang N, Dalli J (2015). 3105:The Journal of Clinical Investigation 2447:Arachidonate 5-lipoxygenase inhibitor 2356:non-steroidal anti-inflammatory drugs 1997:Arachidonate 5-lipoxygenase inhibitor 1054:-eicosatetraenoic acid) or by either 898:) residue to arachidonic acid (i.e. 5 7: 6779:Tooltip Leukotriene B4 ω-hydroxylase 6675:Tooltip Arachidonate 15-lipoxygenase 6637:Tooltip Arachidonate 12-lipoxygenase 4383:Acta Biochimica et Biophysica Sinica 3197:Cellular and Molecular Life Sciences 2347:NSAID-induced non-allergic reactions 2212:, is a 5-LO inhibitor as defined by 2192:, an active constituent of the herb 2005:excessive inflammatory responses to 1388:(ABCC1) and is rapidly converted to 803:Human ALOX5 is a soluble, monomeric 7090:4-Hydroxyphenylpyruvate dioxygenase 6498:Tooltip Arachidonate 5-lipoxygenase 4785:The New England Journal of Medicine 4051:Clinical & Experimental Allergy 3306:American Journal of Cancer Research 2317:specialized pro-resolving mediators 1755:specialized pro-resolving mediators 1658:specialized pro-resolving mediators 1603:specialized pro-resolving mediators 1500:Specialized pro-resolving mediators 1233:s, particularly the α isoform (cPLA 827:catalytic domain (residues 126–673) 5234:Lepley RA, Fitzpatrick FA (1994). 5165:10.1111/j.1432-1033.1995.tb20778.x 4191:Current Allergy and Asthma Reports 4006:Current Allergy and Asthma Reports 3492:Barden AE, Mas E, Mori TA (2016). 2274:drugs in the treatment of asthma. 1942:ALOX5 contributes to non-allergic 1018:, to form the dihydroxyl product, 302: 283: 259: 240: 218: 195: 171: 154: 130: 113: 25: 6910:γ-Linolenic acid (gamolenic acid) 6564:Meclofenamic acid (meclofenamate) 6105:Tooltip Leukotriene B4 receptor 2 5962:Tooltip Leukotriene B4 receptor 1 5823:5-Lipoxygenase activating protein 4148:Steinhilber D, Hofmann B (2014). 2598:10.2174/1389450114666131209110745 2325:5-lipoxygenase-activating protein 2220:Acetyl-keto-beta-boswellic acid ( 1908:Allergy § Signs and symptoms 1806:invasion, trauma, and burns (see 1358:5-hydroxyeicosanoid dehydrogenase 1239:mitogen-activated protein kinases 1176:5-lipoxygenase-activating protein 1140:mitogen-activated protein kinases 819:. Structurally, ALOX5 possesses: 7449: 6869:Tooltip Leukotriene D4 hydrolase 6838:Tooltip Leukotriene C4 hydrolase 6717:Tooltip Leukotriene A4 hydrolase 4638:European Journal of Pharmacology 4583:Tantisira KG, Drazen JM (2009). 3545:PLOS Neglected Tropical Diseases 2878:European Journal of Pharmacology 2830:Cardiovascular Drugs and Therapy 2247:cysteinyl leukotriene receptor 1 2178:chronic obstructive lung disease 1944:NSAID hypersensitivity reactions 1878:reactions and diseases such as: 1308: 1273:-glycerol, 1-hexadecyl-2-acetyl- 954:to its corresponding alcohol, 5( 6962:Prostanoid signaling modulators 6806:Tooltip Leukotriene C4 synthase 5945:Tooltip Leukotriene B4 receptor 3257:British Journal of Pharmacology 2826:"Phospholipase A2 biochemistry" 2744:Haeggström JZ, Funk CD (2011). 2411:single-nucleotide polymorphism 2321:Single nucleotide polymorphism 1763:gene knockout mice exhibit an 1376:(LTA4H) or to leukotriene C4 ( 942:-eicosatetraenoic acid (i.e. 5 778:5-hydroxyeicosatetraenoic acid 640:gene, which occupies 71.9 kilo 1: 7080:Homogentisate 1,2-dioxygenase 6955:Receptor/signaling modulators 5846:Gamma-glutamyl transpeptidase 5834:LTA4 hydrolase (B4 synthesis) 5504:10.1016/S0378-1119(97)00411-3 5253:10.1016/S0021-9258(19)51063-8 5077:10.1016/S0021-9258(18)38066-9 5058:Rouzer CA, Kargman S (1988). 4936:10.1016/S0021-9258(18)54744-X 4890:Biochem. Biophys. Res. Commun 4826:Am. J. Respir. Crit. Care Med 4307:10.1016/s0006-2952(02)01387-4 4092:Fanning LB, Boyce JA (2013). 3498:Current Opinion in Lipidology 3032:10.1016/j.plipres.2013.09.001 2049:Inflammation § Disorders 1841:Inflammation § Disorders 1700:Paracoccidioides brasiliensis 1010:-eicosatetraenoic acid (i.e. 974:-eicosatetraenoic acid (i.e. 748:are ALOX5-negative. In skin, 7497:Peripheral membrane proteins 7056:Arachidonate 15-lipoxygenase 7042:Arachidonate 12-lipoxygenase 5791:Prostaglandin-E2 9-reductase 5312:10.1016/0378-1119(94)90802-8 5283:10.1016/0952-3278(94)90160-0 5187:Proc. Natl. Acad. Sci. U.S.A 5099:Proc. Natl. Acad. Sci. U.S.A 5011:Proc. Natl. Acad. Sci. U.S.A 4958:Proc. Natl. Acad. Sci. U.S.A 4902:10.1016/0006-291X(92)91901-2 4863:10.1007/978-1-4615-0193-0_19 4650:10.1016/j.ejphar.2015.11.001 4549:10.1016/j.bbalip.2014.10.002 3558:10.1371/journal.pntd.0002390 3510:10.1097/MOL.0000000000000262 3078:10.1016/j.bbalip.2005.08.009 3014:Powell WS, Rokach J (2013). 2932:10.1016/j.bbalip.2014.10.008 2914:Powell WS, Rokach J (2015). 2890:10.1016/j.ejphar.2015.03.083 2824:Burke JE, Dennis EA (2009). 2793:10.1007/978-1-4899-0179-8_52 2712:10.1016/j.bbapap.2015.06.003 2650:10.1016/j.bbalip.2014.08.012 2135:Clinical trial § Phases 1707:perforation-induced sepsis, 1488:chronic lymphocytic leukemia 1213:) enzymes. The cytosolic PLA 7095:Indoleamine 2,3-dioxygenase 7051:Arachidonate 8-lipoxygenase 7037:Arachidonate 5-lipoxygenase 5827:Arachidonate 5-lipoxygenase 5527:Arachidonate+5-Lipoxygenase 4632:Duvall MG, Levy BD (2016). 3734:10.1101/cshperspect.a016311 3366:10.1016/j.plefa.2011.04.004 1733:respiratory syncytial virus 1362:5-oxo-eicosatetraenoic acid 782:5-oxo-eicosatetraenoic acid 660:region of ALOX5 contains 8 583:Arachidonate 5-lipoxygenase 388:arachidonate 5-lipoxygenase 33:arachidonate 5-lipoxygenase 7513: 5548:gene details page in the 4601:10.1016/j.jaci.2009.06.035 4282:. MedKoo Biosciences, Inc. 4110:10.1016/j.anai.2013.06.031 3970:10.4049/jimmunol.157.1.336 3863:Nature Reviews. Immunology 3857:Basil MC, Levy BD (2016). 3448:Cell Biology International 3408:10.1016/j.smim.2015.03.004 3020:Progress in Lipid Research 2985:10.1016/j.alit.2014.09.001 2966:Liu M, Yokomizo T (2015). 2030:inflammatory bowel disease 2011:Inflammation § Causes 1994: 1938:Hypersensitivity reactions 1932:platelet-activating factor 1829:inflammatory bowel disease 1808:Inflammation § Causes 1613:ALOX5 acts in series with 1269:such as 1-oleoyl-2-acetyl- 1193:polyunsaturated fatty acid 7327:Michaelis–Menten kinetics 7065:Linoleate 11-lipoxygenase 6946: 4502:10.1007/s00405-016-3983-8 4203:10.1007/s11882-015-0564-7 4018:10.1007/s11882-016-0628-3 3671:Mediators of Inflammation 3209:10.1007/s00018-015-2108-7 2972:Allergology International 2842:10.1007/s10557-008-6132-9 2687:at KEGG Pathway Database. 2674:at KEGG Pathway Database. 1134:may be phosphorylated on 1104:gamma-glutamyltransferase 1060:glutathione S-transferase 876:tyrosine kinase receptors 531: 375: 370: 366: 359: 337: 322: 309: 290: 279: 266: 247: 236: 225: 221: 202: 198: 189: 178: 174: 161: 157: 148: 137: 133: 120: 116: 107: 92: 85: 81: 61: 58: 53: 46: 41: 37: 32: 7219:Diffusion-limited enzyme 5531:Medical Subject Headings 4295:Biochemical Pharmacology 4233:"Flavocoxid Drug Record" 3783:10.4049/jimmunol.1501648 2333:leukotriene-A4 hydrolase 2305:Sp1 transcription factor 2272:beta2-adrenergic agonist 2266:have proven inferior to 2143:chronic myeloid leukemia 1727:infection. Furthermore, 1404:A4 (LxA4) and LxB4 (see 1374:leukotriene-A4 hydrolase 1138:663, 523, and/or 271 by 1016:leukotriene-A4 hydrolase 922:double bonds) to form 5( 752:strongly express ALOX5. 6915:Dihomo-γ-linolenic acid 5439:10.1074/jbc.272.13.8276 5208:10.1073/pnas.92.15.6966 4979:10.1073/pnas.87.23.9073 4334:Cardiovascular Research 2216:studies of the enzyme. 1350:glutathione peroxidases 1201:2 position of membrane 952:glutathione peroxidases 791:splice variants due to 652:encoding the mature 78 5405:10.1006/abio.1995.1444 5345:10.1084/jem.178.6.1935 4260:Clinical trial number 3618:Infection and Immunity 3396:Seminars in Immunology 2706:(10 Pt A): 1365–1371. 2491:10.1073/pnas.86.8.2587 2331:-HpETE, to LTB4 (i.e. 1991:ALOX5-inhibiting drugs 1553:ALOX5 metabolizes the 1432:inflammatory responses 1424:innate immune response 1422:may contribute to the 1400:, to metabolize AA to 1320:ALOX5 metabolizes the 857:adenosine triphosphate 7312:Eadie–Hofstee diagram 7245:Allosteric regulation 7024:: two atoms of oxygen 6851:Serine-borate complex 6017:CGS-23131 (LY-223982) 5742:Diacylglycerol lipase 5595:Non-heme iron protein 5120:10.1073/pnas.85.2.416 3957:Journal of Immunology 3771:Journal of Immunology 2413:(SNP) variant in the 2060:allergic inflammation 1876:allergic inflammation 1785:Clinical significance 1688:Klebsiella pneumoniae 1593:of the E series (see 1559:eicosapentaenoic acid 1549:Eicosapentaenoic acid 1290:, and 1,2-dioctanoyl- 1168:endoplasmic reticulum 7322:Lineweaver–Burk plot 7112:: one atom of oxygen 7085:Cysteine dioxygenase 7075:Catechol dioxygenase 6787:17-Octadecynoic acid 6557:Hypericum perforatum 5662:Tyrosine hydroxylase 5542:genome location and 5032:10.1073/pnas.85.1.26 4798:10.1056/NEJMoa025079 3663:"The acute phase of 3630:10.1128/IAI.02592-14 2586:Current Drug Targets 2264:receptor antagonists 2243:receptor antagonists 2198:molar concentrations 2196:, is active at micro 2137:) combining it with 2020:rheumatoid arthritis 1964:nonallergic rhinitis 1819:rheumatoid arthritis 1769:Lewis lung carcinoma 1694:Borrelia burgdorferi 1619:docosahexaenoic acid 1609:Docosahexaenoic acid 1283:-hexadecyl-2-acetyl- 793:alternative splicing 6882:Ubenimex (bestatin) 6760:Ubenimex (bestatin) 5652:Iron–sulfur protein 5550:UCSC Genome Browser 5474:10.1038/ki.1997.209 5246:(39): 24163–24168. 5199:1995PNAS...92.6966J 5111:1988PNAS...85..416D 5070:(22): 10980–10988. 5023:1988PNAS...85...26M 4970:1990PNAS...87.9073H 4929:(32): 22057–22062. 4396:10.1093/abbs/gmt064 3684:10.1155/2014/893634 3191:Hu Y, Li S (2016). 2482:1989PNAS...86.2587F 2364:shortness of breath 2208:, a constituent of 2062:reactions such as: 2040:Alzheimer's disease 2035:autoimmune diseases 1834:autoimmune diseases 1471:bronchoconstriction 1428:chemotactic factors 1262:chaperone (protein) 1185:chemotactic factors 1086:-(S-glutathionyl)-7 7281:Enzyme superfamily 7214:Enzyme promiscuity 7138:Inositol oxygenase 7119:Firefly luciferase 7100:Chlorite dismutase 7072:other dioxygenase: 6650:3-Methoxytropolone 6574:N-Stearoyldopamine 5647:Inositol oxygenase 4458:10.1002/cncr.25945 4346:10.1093/cvr/cvt339 4268:ClinicalTrials.gov 4167:10.1111/bcpt.12114 3875:10.1038/nri.2015.4 3828:10.1007/bf02536528 3614:infection in mice" 3460:10.1002/cbin.10345 2549:10.1111/bcpt.12115 1948:respiratory system 1664:Transgenic studies 1555:omega-3 fatty acid 1322:omega-6 fatty acid 807:consisting of 673 674:housekeeping genes 624:) substrates into 7437: 7436: 7146: 7145: 6971: 6970: 6890: 6889: 6559:(St. John's Wort) 6485: 6470: 6469: 6466: 6465: 6180: 6179: 5932: 5875: 5874: 5670: 5669: 5432:(13): 8276–8280. 5193:(15): 6966–6970. 4964:(23): 9073–9077. 4872:978-0-306-47283-1 4832:(2 Pt 2): S11–5. 4696:10.1111/all.12260 4690:(10): 1219–1232. 4496:(12): 4111–4117. 4451:(16): 3788–3795. 4418:Kirste S (2009). 4301:(12): 1767–1775. 4063:10.1111/cea.12544 4057:(11): 1673–1680. 3929:10.1111/all.12821 3822:(12): 1184–1188. 3665:Trypanosoma cruzi 3348:and leukotriene B 3269:10.1111/bph.12665 3263:(15): 3551–3574. 3162:10.1159/000074640 3117:10.1172/JCI118480 2802:978-1-4899-0181-1 2762:10.1021/cr200246d 2756:(10): 5866–5898. 2404:chronic urticaria 2396:chronic urticaria 1778:cytotoxic T cells 1742:Toxoplasma gondii 1724:Trypanosoma cruzi 1279:-glycerol, and 1- 762:endothelial cells 580: 579: 576: 575: 479:metabolic pathway 383: 382: 379: 378: 355: 354: 318: 317: 299: 298: 275: 274: 256: 255: 232: 231: 215: 214: 185: 184: 168: 167: 144: 143: 127: 126: 16:(Redirected from 7504: 7492:Lipid metabolism 7454: 7453: 7445: 7317:Hanes–Woolf plot 7260:Enzyme activator 7255:Enzyme inhibitor 7229:Enzyme catalysis 7173: 7166: 7159: 7150: 6998: 6991: 6984: 6975: 6925:Arachidonic acid 6870: 6866: 6839: 6835: 6807: 6803: 6780: 6776: 6718: 6714: 6676: 6672: 6638: 6634: 6598: 6594: 6499: 6495: 6489: 6479: 6445: 6441: 6382: 6378: 6209: 6205: 6196: 6192: 6188: 6106: 6102: 5963: 5959: 5950: 5946: 5942: 5936: 5926: 5902: 5895: 5888: 5879: 5730:Phospholipase A2 5708:lipid metabolism 5697: 5690: 5683: 5674: 5614:Bacterioferritin 5587:Carrier proteins 5580: 5573: 5566: 5557: 5515: 5498:(1–2): 149–156. 5486: 5476: 5467:(5): 1520–1528. 5451: 5441: 5416: 5387: 5366: 5356: 5339:(6): 1935–1946. 5323: 5306:(1–2): 171–174. 5294: 5265: 5255: 5230: 5220: 5210: 5177: 5167: 5142: 5132: 5122: 5089: 5079: 5054: 5044: 5034: 5001: 4991: 4981: 4948: 4938: 4913: 4896:(3): 1482–1490. 4884: 4849: 4811: 4810: 4800: 4776: 4770: 4769: 4758: 4752: 4751: 4740: 4734: 4733: 4722: 4716: 4715: 4678: 4672: 4671: 4661: 4629: 4623: 4622: 4612: 4580: 4571: 4570: 4560: 4528: 4522: 4521: 4485: 4479: 4478: 4460: 4436: 4430: 4429: 4415: 4409: 4408: 4398: 4374: 4368: 4367: 4357: 4325: 4319: 4318: 4290: 4284: 4283: 4276: 4270: 4258: 4252: 4251: 4249: 4248: 4229: 4223: 4222: 4186: 4180: 4179: 4169: 4145: 4132: 4131: 4121: 4089: 4083: 4082: 4046: 4040: 4039: 4029: 3997: 3991: 3990: 3972: 3948: 3942: 3941: 3931: 3906: 3897: 3896: 3886: 3854: 3848: 3847: 3811: 3805: 3804: 3794: 3762: 3756: 3755: 3745: 3713: 3707: 3706: 3696: 3686: 3658: 3652: 3651: 3641: 3624:(3): 1210–1216. 3612:Brucella abortus 3605: 3599: 3598: 3587: 3581: 3580: 3570: 3560: 3536: 3530: 3529: 3489: 3480: 3479: 3443: 3430: 3429: 3419: 3387: 3378: 3377: 3341: 3332: 3331: 3321: 3297: 3291: 3290: 3280: 3248: 3239: 3238: 3220: 3203:(5): 1039–1050. 3188: 3182: 3181: 3145: 3139: 3138: 3128: 3096: 3090: 3089: 3060: 3054: 3053: 3043: 3011: 2998: 2997: 2987: 2963: 2954: 2953: 2943: 2911: 2902: 2901: 2873: 2864: 2863: 2853: 2821: 2815: 2814: 2780: 2774: 2773: 2750:Chemical Reviews 2741: 2724: 2723: 2694: 2688: 2681: 2675: 2668: 2662: 2661: 2633: 2610: 2609: 2581: 2562: 2561: 2551: 2527: 2514: 2513: 2503: 2493: 2476:(8): 2587–2591. 2461: 2368:nasal congestion 1718:Brucella abortus 1703:. In a model of 1386:MRP1 transporter 1326:arachidonic acid 1316:Arachidonic acid 1312: 1289: 1207:phospholipase A2 1164:nuclear membrane 1152:protein kinase C 1148:protein kinase A 890:activity adds a 884:arachidonic acid 813:molecular weight 750:Langerhans cells 702:immune responses 605:iron-containing 585:, also known as 533: 385: 368: 367: 351: 346: 333: 328: 313: 303: 294: 284: 280:RefSeq (protein) 270: 260: 251: 241: 219: 196: 172: 155: 131: 114: 83: 77: 51: 30: 27:Class of enzymes 21: 7512: 7511: 7507: 7506: 7505: 7503: 7502: 7501: 7462: 7461: 7460: 7448: 7440: 7438: 7433: 7345:Oxidoreductases 7331: 7307:Enzyme kinetics 7295: 7291:List of enzymes 7264: 7233: 7204:Catalytic triad 7182: 7177: 7147: 7142: 7123: 7104: 7016: 7005:Oxidoreductases 7002: 6972: 6967: 6942: 6938: 6886: 6868: 6865: 6855: 6837: 6833: 6823: 6805: 6801: 6791: 6778: 6774: 6764: 6716: 6712: 6702: 6674: 6664: 6636: 6626: 6596: 6497: 6478: 6462: 6458: 6443: 6440: 6430: 6411: 6403: 6395: 6380: 6377: 6367: 6238: 6230: 6222: 6207: 6204: 6190: 6176: 6152: 6144: 6104: 6101: 6091: 6007: 5989: 5981: 5961: 5958: 5944: 5925: 5917: 5906: 5876: 5871: 5855: 5809: 5746: 5737:Phospholipase C 5718: 5701: 5671: 5666: 5630: 5597: 5591:metalloproteins 5584: 5523: 5518: 5489: 5454: 5419: 5390: 5369: 5326: 5297: 5268: 5233: 5180: 5152:Eur. J. Biochem 5145: 5092: 5057: 5004: 4951: 4916: 4887: 4873: 4852: 4823: 4819: 4817:Further reading 4814: 4778: 4777: 4773: 4760: 4759: 4755: 4742: 4741: 4737: 4724: 4723: 4719: 4680: 4679: 4675: 4631: 4630: 4626: 4582: 4581: 4574: 4530: 4529: 4525: 4487: 4486: 4482: 4438: 4437: 4433: 4417: 4416: 4412: 4376: 4375: 4371: 4327: 4326: 4322: 4292: 4291: 4287: 4278: 4277: 4273: 4259: 4255: 4246: 4244: 4231: 4230: 4226: 4188: 4187: 4183: 4147: 4146: 4135: 4091: 4090: 4086: 4048: 4047: 4043: 3999: 3998: 3994: 3950: 3949: 3945: 3908: 3907: 3900: 3856: 3855: 3851: 3813: 3812: 3808: 3764: 3763: 3759: 3715: 3714: 3710: 3660: 3659: 3655: 3607: 3606: 3602: 3589: 3588: 3584: 3538: 3537: 3533: 3491: 3490: 3483: 3445: 3444: 3433: 3389: 3388: 3381: 3351: 3347: 3343: 3342: 3335: 3299: 3298: 3294: 3250: 3249: 3242: 3190: 3189: 3185: 3147: 3146: 3142: 3098: 3097: 3093: 3062: 3061: 3057: 3013: 3012: 3001: 2965: 2964: 2957: 2913: 2912: 2905: 2875: 2874: 2867: 2823: 2822: 2818: 2803: 2782: 2781: 2777: 2743: 2742: 2727: 2696: 2695: 2691: 2682: 2678: 2669: 2665: 2635: 2634: 2613: 2583: 2582: 2565: 2529: 2528: 2517: 2463: 2462: 2458: 2454: 2444: 2436:atherosclerosis 2427: 2425:Atherosclerosis 2388:wheal responses 2349: 2293: 2291:Allergic asthma 2280: 2268:corticosteroids 2167:clinical trials 2025:atherosclerosis 1999: 1993: 1940: 1868: 1856:dendritic cells 1824:atherosclerosis 1796:innate immunity 1792: 1787: 1751:innate immunity 1666: 1611: 1587:cytochrome P450 1551: 1512: 1318: 1304: 1267:diacylglycerols 1252: 1248: 1244: 1236: 1232: 1224: 1220: 1216: 1212: 1166:and, probably, 1128: 926:)-hydroperoxy-6 897: 801: 736:express ALOX5. 730:dendritic cells 690: 634: 372:View/Edit Human 349: 344: 331: 326: 323:Location (UCSC) 311: 292: 268: 249: 207: 62: 47: 28: 23: 22: 15: 12: 11: 5: 7510: 7508: 7500: 7499: 7494: 7489: 7484: 7479: 7474: 7464: 7463: 7459: 7458: 7435: 7434: 7432: 7431: 7418: 7405: 7392: 7379: 7366: 7353: 7339: 7337: 7333: 7332: 7330: 7329: 7324: 7319: 7314: 7309: 7303: 7301: 7297: 7296: 7294: 7293: 7288: 7283: 7278: 7272: 7270: 7269:Classification 7266: 7265: 7263: 7262: 7257: 7252: 7247: 7241: 7239: 7235: 7234: 7232: 7231: 7226: 7221: 7216: 7211: 7206: 7201: 7196: 7190: 7188: 7184: 7183: 7178: 7176: 7175: 7168: 7161: 7153: 7144: 7143: 7141: 7140: 7134: 7132: 7125: 7124: 7122: 7121: 7115: 7113: 7106: 7105: 7103: 7102: 7097: 7092: 7087: 7082: 7077: 7068: 7067: 7062: 7053: 7048: 7039: 7027: 7025: 7018: 7017: 7009:monooxygenases 7003: 7001: 7000: 6993: 6986: 6978: 6969: 6968: 6966: 6965: 6958: 6951: 6947: 6944: 6943: 6941: 6940: 6936: 6932: 6927: 6922: 6920:Diacylglycerol 6917: 6912: 6907: 6898: 6896: 6892: 6891: 6888: 6887: 6885: 6884: 6879: 6873: 6871: 6863: 6857: 6856: 6854: 6853: 6848: 6842: 6840: 6831: 6825: 6824: 6822: 6821: 6816: 6810: 6808: 6799: 6793: 6792: 6790: 6789: 6783: 6781: 6772: 6766: 6765: 6763: 6762: 6757: 6752: 6747: 6742: 6737: 6732: 6727: 6721: 6719: 6710: 6704: 6703: 6701: 6700: 6695: 6690: 6685: 6679: 6677: 6666: 6665: 6663: 6662: 6657: 6652: 6647: 6641: 6639: 6628: 6627: 6625: 6624: 6619: 6614: 6609: 6604: 6587: 6586: 6581: 6576: 6571: 6566: 6561: 6553: 6548: 6543: 6538: 6533: 6528: 6523: 6518: 6513: 6508: 6502: 6500: 6486: 6472: 6471: 6468: 6467: 6464: 6463: 6461: 6460: 6456: 6448: 6446: 6438: 6432: 6431: 6429: 6428: 6423: 6414: 6413: 6409: 6405: 6401: 6397: 6393: 6385: 6383: 6375: 6369: 6368: 6366: 6365: 6360: 6355: 6350: 6345: 6340: 6335: 6330: 6325: 6320: 6315: 6310: 6305: 6300: 6295: 6290: 6285: 6280: 6275: 6270: 6265: 6260: 6255: 6250: 6241: 6240: 6236: 6232: 6228: 6224: 6220: 6212: 6210: 6202: 6193: 6182: 6181: 6178: 6177: 6175: 6174: 6169: 6164: 6155: 6154: 6150: 6146: 6142: 6141:20-Hydroxy-LTB 6138: 6133: 6128: 6123: 6118: 6109: 6107: 6099: 6093: 6092: 6090: 6089: 6084: 6079: 6074: 6069: 6064: 6059: 6054: 6049: 6044: 6039: 6034: 6029: 6024: 6019: 6014: 6009: 6005: 6004:20-Carboxy-LTB 5997: 5996: 5991: 5987: 5983: 5979: 5978:20-Hydroxy-LTB 5975: 5966: 5964: 5956: 5947: 5933: 5919: 5918: 5907: 5905: 5904: 5897: 5890: 5882: 5873: 5872: 5870: 5869: 5863: 5861: 5857: 5856: 5854: 5853: 5851:LTD4 hydrolase 5848: 5843: 5837: 5836: 5830: 5829: 5819: 5817: 5811: 5810: 5808: 5807: 5801: 5800: 5794: 5793: 5788: 5782: 5781: 5775: 5774: 5773: 5772: 5767: 5760:Cyclooxygenase 5756: 5754: 5748: 5747: 5745: 5744: 5739: 5733: 5732: 5726: 5724: 5720: 5719: 5702: 5700: 5699: 5692: 5685: 5677: 5668: 5667: 5665: 5664: 5659: 5654: 5649: 5644: 5638: 5636: 5632: 5631: 5629: 5628: 5623: 5618: 5617: 5616: 5605: 5603: 5599: 5598: 5585: 5583: 5582: 5575: 5568: 5560: 5554: 5553: 5534: 5522: 5521:External links 5519: 5517: 5516: 5487: 5452: 5417: 5399:(1): 108–114. 5388: 5378:(3): 145–150. 5372:J Lipid Mediat 5367: 5324: 5295: 5277:(5): 239–243. 5266: 5231: 5178: 5143: 5105:(2): 416–420. 5090: 5055: 5002: 4949: 4914: 4885: 4871: 4850: 4820: 4818: 4815: 4813: 4812: 4771: 4753: 4735: 4717: 4673: 4624: 4595:(3): 422–427. 4572: 4543:(4): 308–330. 4523: 4480: 4431: 4410: 4389:(9): 709–719. 4369: 4340:(3): 522–532. 4320: 4285: 4271: 4253: 4224: 4181: 4133: 4104:(3): 155–162. 4084: 4041: 3992: 3963:(1): 336–342. 3943: 3922:(4): 443–462. 3898: 3849: 3806: 3777:(2): 891–901. 3757: 3728:(2): a016311. 3708: 3653: 3600: 3582: 3531: 3481: 3431: 3402:(3): 200–215. 3379: 3349: 3345: 3333: 3312:(4): 347–355. 3292: 3240: 3183: 3156:(4): 285–294. 3140: 3111:(3): 806–813. 3091: 3072:(3): 228–236. 3055: 3026:(4): 651–665. 2999: 2955: 2926:(4): 340–355. 2903: 2865: 2816: 2801: 2775: 2725: 2689: 2676: 2663: 2644:(4): 331–339. 2611: 2592:(4): 410–422. 2563: 2515: 2455: 2453: 2450: 2443: 2440: 2426: 2423: 2380:rhinosinusitis 2348: 2345: 2292: 2289: 2279: 2278:Human genetics 2276: 2194:St John's wort 2119: 2118: 2115: 2114: 2113: 2108: 2103: 2102:conjunctivitis 2100: 2097: 2091: 2090: 2089: 2084: 2079: 2074: 2072:conjunctivitis 2069: 2045: 2044: 2043: 2042: 2037: 2032: 2027: 2022: 2014: 1995:Main article: 1992: 1989: 1984: 1983: 1977: 1972: 1970:conjunctivitis 1966: 1961: 1939: 1936: 1912: 1911: 1901: 1896: 1891: 1889:conjunctivitis 1886: 1867: 1864: 1837: 1836: 1831: 1826: 1821: 1812: 1811: 1791: 1788: 1786: 1783: 1774:T helper cells 1665: 1662: 1610: 1607: 1583:cyclooxygenase 1550: 1547: 1511: 1508: 1480:conjunctivitis 1317: 1314: 1303: 1300: 1250: 1246: 1242: 1234: 1230: 1222: 1218: 1217:set (i.e. cPLA 1214: 1210: 1127: 1124: 1058:or microsomal 1020:leukotriene B4 982:-HpETE to its 946:-HpETE). The 5 895: 880: 879: 860: 853: 846: 835:C2-like domain 828: 800: 797: 689: 686: 648:divided by 13 633: 630: 591:5-lipoxygenase 578: 577: 574: 573: 568: 562: 561: 556: 550: 549: 544: 538: 537: 529: 528: 519: 513: 512: 501: 494: 493: 488: 482: 481: 476: 470: 469: 464: 458: 457: 452: 446: 445: 440: 434: 433: 428: 422: 421: 417: 416: 413: 407: 406: 401: 395: 394: 390: 389: 381: 380: 377: 376: 374: 364: 363: 357: 356: 353: 352: 347: 342: 335: 334: 329: 324: 320: 319: 316: 315: 307: 306: 300: 297: 296: 288: 287: 281: 277: 276: 273: 272: 264: 263: 257: 254: 253: 245: 244: 238: 234: 233: 230: 229: 223: 222: 216: 213: 212: 200: 199: 193: 187: 186: 183: 182: 176: 175: 169: 166: 165: 159: 158: 152: 146: 145: 142: 141: 135: 134: 128: 125: 124: 118: 117: 111: 105: 104: 99: 94: 90: 89: 79: 78: 60: 56: 55: 54:5-lipoxygenase 52: 44: 43: 39: 38: 35: 34: 26: 24: 18:5-lipoxygenase 14: 13: 10: 9: 6: 4: 3: 2: 7509: 7498: 7495: 7493: 7490: 7488: 7485: 7483: 7480: 7478: 7475: 7473: 7470: 7469: 7467: 7457: 7452: 7447: 7443: 7429: 7425: 7424: 7419: 7416: 7412: 7411: 7406: 7403: 7399: 7398: 7393: 7390: 7386: 7385: 7380: 7377: 7373: 7372: 7367: 7364: 7360: 7359: 7354: 7351: 7347: 7346: 7341: 7340: 7338: 7334: 7328: 7325: 7323: 7320: 7318: 7315: 7313: 7310: 7308: 7305: 7304: 7302: 7298: 7292: 7289: 7287: 7286:Enzyme family 7284: 7282: 7279: 7277: 7274: 7273: 7271: 7267: 7261: 7258: 7256: 7253: 7251: 7250:Cooperativity 7248: 7246: 7243: 7242: 7240: 7236: 7230: 7227: 7225: 7222: 7220: 7217: 7215: 7212: 7210: 7209:Oxyanion hole 7207: 7205: 7202: 7200: 7197: 7195: 7192: 7191: 7189: 7185: 7181: 7174: 7169: 7167: 7162: 7160: 7155: 7154: 7151: 7139: 7136: 7135: 7133: 7130: 7126: 7120: 7117: 7116: 7114: 7111: 7107: 7101: 7098: 7096: 7093: 7091: 7088: 7086: 7083: 7081: 7078: 7076: 7073: 7070: 7069: 7066: 7063: 7061: 7057: 7054: 7052: 7049: 7047: 7043: 7040: 7038: 7035: 7033: 7029: 7028: 7026: 7023: 7019: 7014: 7010: 7006: 6999: 6994: 6992: 6987: 6985: 6980: 6979: 6976: 6964: 6963: 6959: 6957: 6956: 6952: 6949: 6948: 6945: 6939: 6935:Leukotriene A 6933: 6931: 6928: 6926: 6923: 6921: 6918: 6916: 6913: 6911: 6908: 6906: 6905:Linoleic acid 6903: 6900: 6899: 6897: 6893: 6883: 6880: 6878: 6875: 6874: 6872: 6867: 6858: 6852: 6849: 6847: 6844: 6843: 6841: 6836: 6826: 6820: 6817: 6815: 6812: 6811: 6809: 6804: 6794: 6788: 6785: 6784: 6782: 6777: 6767: 6761: 6758: 6756: 6753: 6751: 6748: 6746: 6743: 6741: 6738: 6736: 6733: 6731: 6728: 6726: 6723: 6722: 6720: 6715: 6705: 6699: 6696: 6694: 6691: 6689: 6686: 6684: 6681: 6680: 6678: 6673: 6667: 6661: 6658: 6656: 6653: 6651: 6648: 6646: 6643: 6642: 6640: 6635: 6629: 6623: 6620: 6618: 6615: 6613: 6610: 6608: 6605: 6603: 6600: 6595: 6589: 6588: 6585: 6582: 6580: 6577: 6575: 6572: 6570: 6567: 6565: 6562: 6560: 6558: 6554: 6552: 6549: 6547: 6544: 6542: 6539: 6537: 6534: 6532: 6529: 6527: 6524: 6522: 6519: 6517: 6514: 6512: 6509: 6507: 6504: 6503: 6501: 6496: 6490: 6487: 6483: 6477: 6473: 6459: 6455:Leukotriene E 6453: 6450: 6449: 6447: 6442: 6433: 6427: 6424: 6422: 6419: 6416: 6415: 6412: 6408:Leukotriene E 6406: 6404: 6400:Leukotriene D 6398: 6396: 6392:Leukotriene C 6390: 6387: 6386: 6384: 6379: 6370: 6364: 6361: 6359: 6356: 6354: 6351: 6349: 6346: 6344: 6341: 6339: 6336: 6334: 6331: 6329: 6326: 6324: 6321: 6319: 6316: 6314: 6311: 6309: 6306: 6304: 6301: 6299: 6296: 6294: 6291: 6289: 6286: 6284: 6281: 6279: 6276: 6274: 6271: 6269: 6266: 6264: 6261: 6259: 6256: 6254: 6251: 6249: 6246: 6243: 6242: 6239: 6235:Leukotriene E 6233: 6231: 6227:Leukotriene D 6225: 6223: 6219:Leukotriene C 6217: 6214: 6213: 6211: 6206: 6197: 6194: 6189: 6183: 6173: 6170: 6168: 6165: 6163: 6160: 6157: 6156: 6153: 6149:Leukotriene B 6147: 6145: 6139: 6137: 6134: 6132: 6129: 6127: 6124: 6122: 6119: 6117: 6114: 6111: 6110: 6108: 6103: 6094: 6088: 6085: 6083: 6080: 6078: 6075: 6073: 6070: 6068: 6065: 6063: 6060: 6058: 6055: 6053: 6050: 6048: 6045: 6043: 6040: 6038: 6035: 6033: 6030: 6028: 6025: 6023: 6020: 6018: 6015: 6013: 6010: 6008: 6002: 5999: 5998: 5995: 5992: 5990: 5986:Leukotriene B 5984: 5982: 5976: 5974: 5971: 5968: 5967: 5965: 5960: 5951: 5948: 5943: 5937: 5934: 5930: 5924: 5920: 5916: 5913: 5910: 5903: 5898: 5896: 5891: 5889: 5884: 5883: 5880: 5868: 5865: 5864: 5862: 5858: 5852: 5849: 5847: 5844: 5842: 5841:LTC4 synthase 5839: 5838: 5835: 5832: 5831: 5828: 5824: 5821: 5820: 5818: 5816: 5812: 5806: 5803: 5802: 5799: 5798:PGI2 synthase 5796: 5795: 5792: 5789: 5787: 5784: 5783: 5780: 5779:PGD2 synthase 5777: 5776: 5771: 5768: 5766: 5763: 5762: 5761: 5758: 5757: 5755: 5753: 5749: 5743: 5740: 5738: 5735: 5734: 5731: 5728: 5727: 5725: 5721: 5717: 5713: 5709: 5705: 5698: 5693: 5691: 5686: 5684: 5679: 5678: 5675: 5663: 5660: 5658: 5655: 5653: 5650: 5648: 5645: 5643: 5640: 5639: 5637: 5633: 5627: 5624: 5622: 5619: 5615: 5612: 5611: 5610: 5607: 5606: 5604: 5600: 5596: 5592: 5588: 5581: 5576: 5574: 5569: 5567: 5562: 5561: 5558: 5551: 5547: 5546: 5541: 5540: 5535: 5532: 5528: 5525: 5524: 5520: 5513: 5509: 5505: 5501: 5497: 5493: 5488: 5484: 5480: 5475: 5470: 5466: 5462: 5458: 5453: 5449: 5445: 5440: 5435: 5431: 5427: 5426:J. Biol. Chem 5423: 5418: 5414: 5410: 5406: 5402: 5398: 5394: 5393:Anal. Biochem 5389: 5385: 5381: 5377: 5373: 5368: 5364: 5360: 5355: 5350: 5346: 5342: 5338: 5334: 5330: 5325: 5321: 5317: 5313: 5309: 5305: 5301: 5296: 5292: 5288: 5284: 5280: 5276: 5272: 5267: 5263: 5259: 5254: 5249: 5245: 5241: 5240:J. Biol. Chem 5237: 5232: 5228: 5224: 5219: 5214: 5209: 5204: 5200: 5196: 5192: 5188: 5184: 5179: 5175: 5171: 5166: 5161: 5157: 5153: 5149: 5144: 5140: 5136: 5131: 5126: 5121: 5116: 5112: 5108: 5104: 5100: 5096: 5091: 5087: 5083: 5078: 5073: 5069: 5065: 5064:J. Biol. Chem 5061: 5056: 5052: 5048: 5043: 5038: 5033: 5028: 5024: 5020: 5016: 5012: 5008: 5003: 4999: 4995: 4990: 4985: 4980: 4975: 4971: 4967: 4963: 4959: 4955: 4950: 4946: 4942: 4937: 4932: 4928: 4924: 4923:J. Biol. Chem 4920: 4915: 4911: 4907: 4903: 4899: 4895: 4891: 4886: 4882: 4878: 4874: 4868: 4864: 4860: 4856: 4851: 4847: 4843: 4839: 4835: 4831: 4827: 4822: 4821: 4816: 4808: 4804: 4799: 4794: 4790: 4786: 4782: 4775: 4772: 4767: 4763: 4757: 4754: 4749: 4745: 4739: 4736: 4731: 4727: 4721: 4718: 4713: 4709: 4705: 4701: 4697: 4693: 4689: 4685: 4677: 4674: 4669: 4665: 4660: 4655: 4651: 4647: 4643: 4639: 4635: 4628: 4625: 4620: 4616: 4611: 4606: 4602: 4598: 4594: 4590: 4586: 4579: 4577: 4573: 4568: 4564: 4559: 4554: 4550: 4546: 4542: 4538: 4534: 4527: 4524: 4519: 4515: 4511: 4507: 4503: 4499: 4495: 4491: 4484: 4481: 4476: 4472: 4468: 4464: 4459: 4454: 4450: 4446: 4442: 4435: 4432: 4427: 4423: 4422: 4414: 4411: 4406: 4402: 4397: 4392: 4388: 4384: 4380: 4373: 4370: 4365: 4361: 4356: 4351: 4347: 4343: 4339: 4335: 4331: 4324: 4321: 4316: 4312: 4308: 4304: 4300: 4296: 4289: 4286: 4281: 4275: 4272: 4269: 4265: 4264: 4257: 4254: 4243:on 2019-08-19 4242: 4238: 4234: 4228: 4225: 4220: 4216: 4212: 4208: 4204: 4200: 4196: 4192: 4185: 4182: 4177: 4173: 4168: 4163: 4159: 4155: 4151: 4144: 4142: 4140: 4138: 4134: 4129: 4125: 4120: 4115: 4111: 4107: 4103: 4099: 4095: 4088: 4085: 4080: 4076: 4072: 4068: 4064: 4060: 4056: 4052: 4045: 4042: 4037: 4033: 4028: 4023: 4019: 4015: 4011: 4007: 4003: 3996: 3993: 3988: 3984: 3980: 3976: 3971: 3966: 3962: 3958: 3954: 3947: 3944: 3939: 3935: 3930: 3925: 3921: 3917: 3913: 3905: 3903: 3899: 3894: 3890: 3885: 3880: 3876: 3872: 3868: 3864: 3860: 3853: 3850: 3845: 3841: 3837: 3833: 3829: 3825: 3821: 3817: 3810: 3807: 3802: 3798: 3793: 3788: 3784: 3780: 3776: 3772: 3768: 3761: 3758: 3753: 3749: 3744: 3739: 3735: 3731: 3727: 3723: 3719: 3712: 3709: 3704: 3700: 3695: 3690: 3685: 3680: 3676: 3672: 3668: 3666: 3657: 3654: 3649: 3645: 3640: 3635: 3631: 3627: 3623: 3619: 3615: 3613: 3604: 3601: 3596: 3592: 3586: 3583: 3578: 3574: 3569: 3564: 3559: 3554: 3550: 3546: 3542: 3535: 3532: 3527: 3523: 3519: 3515: 3511: 3507: 3503: 3499: 3495: 3488: 3486: 3482: 3477: 3473: 3469: 3465: 3461: 3457: 3453: 3449: 3442: 3440: 3438: 3436: 3432: 3427: 3423: 3418: 3413: 3409: 3405: 3401: 3397: 3393: 3386: 3384: 3380: 3375: 3371: 3367: 3363: 3359: 3355: 3340: 3338: 3334: 3329: 3325: 3320: 3315: 3311: 3307: 3303: 3296: 3293: 3288: 3284: 3279: 3274: 3270: 3266: 3262: 3258: 3254: 3247: 3245: 3241: 3236: 3232: 3228: 3224: 3219: 3214: 3210: 3206: 3202: 3198: 3194: 3187: 3184: 3179: 3175: 3171: 3167: 3163: 3159: 3155: 3151: 3144: 3141: 3136: 3132: 3127: 3122: 3118: 3114: 3110: 3106: 3102: 3095: 3092: 3087: 3083: 3079: 3075: 3071: 3067: 3059: 3056: 3051: 3047: 3042: 3037: 3033: 3029: 3025: 3021: 3017: 3010: 3008: 3006: 3004: 3000: 2995: 2991: 2986: 2981: 2977: 2973: 2969: 2962: 2960: 2956: 2951: 2947: 2942: 2937: 2933: 2929: 2925: 2921: 2917: 2910: 2908: 2904: 2899: 2895: 2891: 2887: 2883: 2879: 2872: 2870: 2866: 2861: 2857: 2852: 2847: 2843: 2839: 2835: 2831: 2827: 2820: 2817: 2812: 2808: 2804: 2798: 2794: 2790: 2786: 2779: 2776: 2771: 2767: 2763: 2759: 2755: 2751: 2747: 2740: 2738: 2736: 2734: 2732: 2730: 2726: 2721: 2717: 2713: 2709: 2705: 2701: 2693: 2690: 2686: 2680: 2677: 2673: 2667: 2664: 2659: 2655: 2651: 2647: 2643: 2639: 2632: 2630: 2628: 2626: 2624: 2622: 2620: 2618: 2616: 2612: 2607: 2603: 2599: 2595: 2591: 2587: 2580: 2578: 2576: 2574: 2572: 2570: 2568: 2564: 2559: 2555: 2550: 2545: 2541: 2537: 2533: 2526: 2524: 2522: 2520: 2516: 2511: 2507: 2502: 2497: 2492: 2487: 2483: 2479: 2475: 2471: 2467: 2460: 2457: 2451: 2449: 2448: 2441: 2439: 2437: 2432: 2424: 2422: 2420: 2416: 2412: 2409: 2405: 2401: 2397: 2393: 2389: 2385: 2381: 2377: 2373: 2369: 2365: 2361: 2357: 2353: 2346: 2344: 2342: 2338: 2334: 2330: 2326: 2322: 2318: 2314: 2310: 2306: 2302: 2299:in the human 2298: 2295:The upstream 2290: 2288: 2286: 2277: 2275: 2273: 2269: 2265: 2259: 2257: 2253: 2248: 2244: 2240: 2236: 2232: 2227: 2225: 2223: 2217: 2215: 2211: 2207: 2203: 2199: 2195: 2191: 2190: 2185: 2183: 2179: 2175: 2171: 2168: 2164: 2160: 2156: 2155: 2150: 2148: 2144: 2141:for treating 2140: 2136: 2132: 2131:acne vulgaris 2126: 2124: 2116: 2112: 2109: 2107: 2104: 2101: 2098: 2095: 2094: 2092: 2088: 2085: 2083: 2080: 2078: 2075: 2073: 2070: 2068: 2064: 2063: 2061: 2057: 2054: 2053: 2052: 2050: 2041: 2038: 2036: 2033: 2031: 2028: 2026: 2023: 2021: 2018: 2017: 2015: 2012: 2008: 2004: 2003: 2002: 1998: 1990: 1988: 1981: 1978: 1976: 1973: 1971: 1968:non-allergic 1967: 1965: 1962: 1960: 1957: 1956: 1955: 1953: 1949: 1945: 1937: 1935: 1933: 1929: 1925: 1921: 1917: 1909: 1905: 1902: 1900: 1897: 1895: 1892: 1890: 1887: 1885: 1881: 1880: 1879: 1877: 1873: 1865: 1863: 1861: 1857: 1853: 1849: 1844: 1842: 1835: 1832: 1830: 1827: 1825: 1822: 1820: 1817: 1816: 1815: 1809: 1805: 1801: 1800: 1799: 1797: 1789: 1784: 1782: 1779: 1775: 1770: 1766: 1762: 1758: 1756: 1752: 1748: 1745:disease, and 1744: 1743: 1738: 1734: 1730: 1726: 1725: 1720: 1719: 1714: 1710: 1706: 1702: 1701: 1696: 1695: 1690: 1689: 1684: 1683:gene knockout 1681: 1677: 1675: 1671: 1663: 1661: 1659: 1655: 1652:The D series 1650: 1648: 1644: 1640: 1636: 1632: 1628: 1624: 1620: 1616: 1608: 1606: 1604: 1598: 1596: 1592: 1588: 1584: 1580: 1576: 1572: 1568: 1564: 1560: 1556: 1548: 1546: 1544: 1540: 1536: 1532: 1528: 1524: 1520: 1516: 1509: 1507: 1505: 1501: 1497: 1491: 1489: 1485: 1481: 1477: 1472: 1468: 1464: 1460: 1456: 1452: 1450: 1446: 1442: 1437: 1433: 1429: 1426:as leukocyte 1425: 1421: 1417: 1413: 1409: 1407: 1403: 1399: 1395: 1391: 1387: 1383: 1382:LTC4 synthase 1379: 1375: 1371: 1367: 1363: 1359: 1355: 1351: 1347: 1343: 1339: 1335: 1331: 1327: 1323: 1315: 1313: 1311: 1301: 1299: 1297: 1293: 1287: 1282: 1278: 1277: 1272: 1268: 1263: 1259: 1254: 1240: 1228: 1225:enzymes (see 1208: 1204: 1203:phospholipids 1200: 1199: 1194: 1189: 1186: 1181: 1177: 1173: 1169: 1165: 1161: 1157: 1153: 1149: 1145: 1141: 1137: 1133: 1125: 1123: 1121: 1115: 1113: 1109: 1105: 1101: 1097: 1093: 1089: 1085: 1081: 1077: 1073: 1069: 1065: 1061: 1057: 1056:LTC4 synthase 1053: 1049: 1045: 1041: 1037: 1033: 1029: 1025: 1022:(LTB4, i.e. 5 1021: 1017: 1013: 1009: 1005: 1001: 997: 993: 989: 985: 981: 977: 973: 969: 965: 961: 957: 953: 949: 945: 941: 937: 933: 929: 925: 921: 917: 913: 909: 905: 901: 893: 889: 885: 877: 873: 869: 865: 861: 858: 854: 851: 847: 844: 840: 836: 833: 829: 826: 822: 821: 820: 818: 814: 810: 806: 798: 796: 794: 790: 785: 783: 779: 773: 771: 767: 763: 759: 758:smooth muscle 755: 751: 747: 743: 739: 735: 734:B-lymphocytes 731: 727: 723: 719: 715: 711: 707: 703: 699: 695: 687: 685: 683: 679: 675: 671: 667: 663: 659: 658:gene promoter 655: 651: 647: 643: 639: 631: 629: 627: 623: 619: 615: 612: 608: 604: 600: 596: 592: 588: 584: 572: 569: 567: 563: 560: 557: 555: 551: 548: 545: 543: 539: 534: 530: 527: 523: 520: 518: 517:Gene Ontology 514: 511: 508: 505: 502: 499: 495: 492: 489: 487: 483: 480: 477: 475: 471: 468: 465: 463: 459: 456: 455:NiceZyme view 453: 451: 447: 444: 441: 439: 435: 432: 429: 427: 423: 418: 414: 412: 408: 405: 402: 400: 396: 391: 386: 373: 369: 365: 362: 358: 348: 343: 340: 336: 330: 325: 321: 314: 308: 304: 301: 295: 289: 285: 282: 278: 271: 265: 261: 258: 252: 246: 242: 239: 237:RefSeq (mRNA) 235: 228: 224: 220: 217: 211: 210: 206: 201: 197: 194: 192: 188: 181: 177: 173: 170: 164: 160: 156: 153: 151: 147: 140: 136: 132: 129: 123: 119: 115: 112: 110: 106: 103: 100: 98: 95: 91: 88: 84: 80: 76: 72: 68: 65: 57: 50: 45: 40: 36: 31: 19: 7423:Translocases 7420: 7407: 7394: 7381: 7368: 7358:Transferases 7355: 7342: 7199:Binding site 7071: 7036: 7032:lipoxygenase 7030: 6960: 6953: 6901: 6745:JNJ-26993135 6740:Fosinoprilat 6590: 6556: 6526:Caffeic acid 6492: 6451: 6418:Antagonists: 6417: 6388: 6245:Antagonists: 6244: 6215: 6159:Antagonists: 6158: 6112: 6001:Antagonists: 6000: 5969: 5826: 5815:Leukotrienes 5805:TXA synthase 5786:PGE synthase 5657:Lipoxygenase 5544: 5538: 5495: 5491: 5464: 5460: 5429: 5425: 5396: 5392: 5375: 5371: 5336: 5332: 5303: 5299: 5274: 5270: 5243: 5239: 5190: 5186: 5158:(1): 37–46. 5155: 5151: 5102: 5098: 5067: 5063: 5017:(1): 26–30. 5014: 5010: 4961: 4957: 4926: 4922: 4893: 4889: 4854: 4829: 4825: 4791:(1): 29–37. 4788: 4784: 4774: 4765: 4756: 4747: 4738: 4729: 4720: 4687: 4683: 4676: 4641: 4637: 4627: 4592: 4588: 4540: 4536: 4526: 4493: 4489: 4483: 4448: 4444: 4434: 4425: 4420: 4413: 4386: 4382: 4372: 4337: 4333: 4323: 4298: 4294: 4288: 4280:"PF-4191834" 4274: 4261: 4256: 4245:. Retrieved 4241:the original 4236: 4227: 4194: 4190: 4184: 4160:(1): 70–77. 4157: 4153: 4101: 4097: 4087: 4054: 4050: 4044: 4009: 4005: 3995: 3960: 3956: 3946: 3919: 3915: 3869:(1): 51–67. 3866: 3862: 3852: 3819: 3815: 3809: 3774: 3770: 3760: 3725: 3721: 3711: 3674: 3670: 3664: 3656: 3621: 3617: 3611: 3603: 3594: 3585: 3551:(8): e2390. 3548: 3544: 3534: 3504:(1): 26–32. 3501: 3497: 3451: 3447: 3399: 3395: 3360:(1): 37–41. 3357: 3353: 3309: 3305: 3295: 3260: 3256: 3200: 3196: 3186: 3153: 3149: 3143: 3108: 3104: 3094: 3069: 3065: 3058: 3023: 3019: 2978:(1): 17–26. 2975: 2971: 2923: 2919: 2881: 2877: 2836:(1): 49–59. 2833: 2829: 2819: 2784: 2778: 2753: 2749: 2703: 2699: 2692: 2679: 2666: 2641: 2637: 2589: 2585: 2542:(1): 78–82. 2539: 2535: 2473: 2469: 2459: 2445: 2430: 2428: 2418: 2414: 2399: 2383: 2359: 2350: 2328: 2300: 2294: 2284: 2281: 2260: 2228: 2219: 2218: 2187: 2186: 2181: 2173: 2172: 2170:flavocoxid. 2152: 2151: 2127: 2120: 2046: 2000: 1985: 1941: 1927: 1919: 1915: 1913: 1869: 1859: 1851: 1847: 1845: 1838: 1813: 1793: 1790:Inflammation 1764: 1760: 1759: 1740: 1737:Lyme disease 1728: 1722: 1716: 1708: 1698: 1692: 1686: 1679: 1678: 1669: 1667: 1651: 1642: 1638: 1634: 1630: 1626: 1622: 1621:(DHA, i.e. 4 1612: 1599: 1578: 1574: 1570: 1566: 1562: 1561:(EPA, i.e. 4 1552: 1542: 1538: 1534: 1530: 1526: 1522: 1518: 1513: 1492: 1453: 1410: 1392:and then to 1360:(5-HEDH) to 1341: 1337: 1333: 1329: 1319: 1305: 1295: 1291: 1285: 1280: 1274: 1270: 1255: 1196: 1190: 1179: 1171: 1159: 1131: 1129: 1116: 1099: 1095: 1091: 1087: 1083: 1079: 1051: 1047: 1043: 1039: 1035: 1031: 1030:-dihydroxy-5 1027: 1023: 1007: 1003: 999: 995: 991: 987: 979: 971: 967: 963: 959: 955: 947: 943: 939: 935: 931: 927: 923: 919: 915: 911: 907: 903: 899: 892:hydroperoxyl 881: 802: 799:Biochemistry 786: 774: 746:erythrocytes 700:, and other 694:inflammation 691: 637: 635: 626:leukotrienes 618:lipoxygenase 610: 598: 594: 590: 586: 582: 581: 443:BRENDA entry 310: 291: 267: 248: 226: 203: 179: 162: 138: 121: 101: 96: 59:External IDs 7487:Eicosanoids 7472:Human genes 7194:Active site 6902:Precursors: 6725:Acebilustat 6599:inhibitors: 6569:Minocycline 6358:Zafirlukast 6303:Montelukast 5909:Leukotriene 5752:Prostanoids 5714:metabolism 5642:Hemerythrin 5626:Transferrin 5621:Lactoferrin 5333:J. Exp. Med 4644:: 144–155. 4263:NCT00404313 3454:(1): 3–22. 2252:sleep apnea 2235:Zafirlukast 2231:Montelukast 1776:and CD8+ T 1533:)-hydroxy-6 1436:eosinophils 1328:(AA, i.e. 5 958:)-hydroxy-6 888:dioxygenase 868:SH3 domains 850:PLAT domain 809:amino acids 754:Fibroblasts 722:macrophages 710:eosinophils 706:neutrophils 601:, is a non- 431:IntEnz view 393:Identifiers 75:- orthologs 42:Identifiers 7477:EC 1.13.11 7466:Categories 7397:Isomerases 7371:Hydrolases 7238:Regulation 6877:Cilastatin 6814:Azelastine 6579:Timegadine 6551:Hyperforin 6482:inhibitors 6348:Tomelukast 6343:Tipelukast 6328:SKF-104353 6323:Ritolukast 6318:Pranlukast 6313:Pobilukast 6293:Masilukast 6278:ICI-198615 6268:Cinalukast 6077:Ticolubant 6047:Moxilubant 6022:CGS-25019C 5915:modulators 5712:eicosanoid 5704:Metabolism 5461:Kidney Int 4766:NCBI dbSNP 4748:NCBI dbSNP 4730:NCBI dbSNP 4247:2016-08-22 4197:(11): 64. 3677:: 893634. 2452:References 2392:angioedema 2372:rhinorrhea 2354:and other 2309:Homozygous 2239:Pranlukast 2189:Hyperforin 2182:PF-4191834 2174:Setileuton 2154:Flavocoxid 2106:angioedema 1980:urticarial 1975:angioedema 1924:eosinophil 1713:peritoneum 1170:membrane; 1126:Regulation 1082:-hydroxy,6 994:-hydroxy-6 886:. ALOX5's 832:N-terminal 825:C-terminal 766:leukocytes 760:cells and 726:mast cells 688:Expression 666:TATA boxes 664:but lacks 654:kilodalton 642:base pairs 500:structures 467:KEGG entry 415:80619-02-9 404:1.13.11.34 7276:EC number 6755:SC-57461A 6730:Captopril 6698:PD-146176 6655:Baicalein 6546:Fenleuton 6511:Baicalein 6452:Agonists: 6389:Agonists: 6353:Verlukast 6288:LY-170680 6283:Iralukast 6273:FPL-55712 6216:Agonists: 6172:ZK-158252 6167:LY-255283 6162:CP-195543 6113:Agonists: 6087:ZK-158252 6067:SB-209247 6042:LY-293111 6032:CP-195543 6027:CP-105696 6012:Amelubant 5994:LY-255283 5970:Agonists: 5912:signaling 5860:Ungrouped 5723:Precursor 4012:(7): 48. 3595:WikiGenes 2884:: 49–63. 2683:Reaction 2670:Reaction 2366:, and/or 2262:and LTD4 2202:indirubin 2163:Catechins 2111:urticaria 2065:allergic 2007:pathogens 1954:such as: 1882:allergic 1735:disease, 1674:pathogens 1654:resolvins 1591:resolvins 1515:Mead acid 1510:Mead acid 1496:apoptosis 1484:urticaria 1441:apoptosis 1420:5-oxo-ETE 1288:-glycerol 1221:s) of PLA 1144:S6 kinase 1068:glutamate 738:Platelets 718:monocytes 714:basophils 670:CAT boxes 420:Databases 87:Orthologs 64:GeneCards 7300:Kinetics 7224:Cofactor 7187:Activity 6950:See also 6846:Acivicin 6693:Luteolin 6612:BAYx1005 6584:Zileuton 6541:Curcumin 6536:CJ-13610 6426:BAYu9916 6421:BAYu9773 6338:Sulukast 6308:ONO-1078 6263:BAYx7195 6258:BAYu9916 6253:BAYu9773 6248:Ablukast 6136:15-HpETE 6126:12-HpETE 6072:SC-53228 6062:RP-69698 6057:RG-14893 6052:ONO-4057 6037:Etalocib 5923:Receptor 5609:Ferritin 4881:12664574 4846:10673219 4807:14702425 4712:32169451 4704:24117484 4668:26546247 4619:19665766 4567:25316652 4518:31311115 4510:26980339 4475:11283379 4467:21287538 4405:23752617 4364:24368834 4315:12445866 4237:LiverTox 4219:38854822 4211:26385352 4176:23953428 4128:23987187 4079:32499209 4071:25818037 4036:27333777 3987:35264541 3938:26678823 3893:26688348 3801:26663781 3752:25359497 3703:25165415 3648:25583526 3577:23991239 3526:45820130 3518:26655290 3476:10160642 3468:25052386 3426:25857211 3374:21530211 3328:23977445 3287:24588652 3227:26686687 3218:11108378 3178:22159108 3170:14707447 3150:Oncology 3086:16154383 3050:24056189 2994:25572555 2950:25449650 2898:25895638 2860:18931897 2770:21936577 2720:26066610 2658:25152163 2606:24313690 2558:24020397 2442:See also 2297:promoter 2245:for the 2214:in vitro 2210:turmeric 2206:curcumin 2159:Baicalin 2139:imatinib 2123:Zileuton 2099:rhinitis 2067:rhinitis 1884:rhinitis 1804:pathogen 1765:increase 1476:rhinitis 1072:cysteine 894:(i.e. HO 870:such as 662:GC boxes 571:proteins 559:articles 547:articles 504:RCSB PDB 361:Wikidata 7482:Enzymes 7456:Biology 7410:Ligases 7180:Enzymes 7131:: other 7129:1.13.99 7110:1.13.12 7022:1.13.11 6750:SA-6541 6521:BW-B70C 6363:ZD-3523 6333:SR-2640 6131:15-HETE 6116:12-HETE 6082:U-75302 5973:12-HETE 5929:ligands 5716:enzymes 5635:nonheme 5512:9373149 5483:9150468 5448:9079648 5413:8585605 5384:8268460 5363:8245774 5354:2191287 5320:8125298 5291:8066098 5262:7929073 5227:7624354 5195:Bibcode 5174:7556168 5139:3422434 5107:Bibcode 5086:3134355 5051:2829172 5019:Bibcode 4998:2251250 4966:Bibcode 4945:1939225 4910:1540191 4684:Allergy 4659:4854800 4610:2794036 4558:4370320 4355:3928003 4119:4088989 4027:5515624 3979:8683135 3916:Allergy 3884:5242505 3844:3964822 3836:1668115 3792:4705594 3743:4315926 3694:4137569 3639:4333460 3568:3749973 3417:4515371 3319:3744015 3278:4128057 3235:2744344 3135:8609238 3041:5710732 2941:5710736 2851:2823292 2811:9131168 2510:2565035 2478:Bibcode 2408:genetic 2406:). The 2390:and/or 2378:and/or 2352:Aspirin 2341:CYSLTR2 2337:CYSLTR1 2056:allergy 1946:of the 1872:allergy 1866:Allergy 1747:corneal 1517:(i.e. 5 1504:Lipoxin 1402:lipoxin 1346:5-HpETE 1258:F actin 1150:(PKA), 1076:glycine 984:epoxide 864:proline 845:protein 841:), and 815:of ~78 811:with a 805:protein 742:T cells 704:, e.g. 698:allergy 650:introns 526:QuickGO 491:profile 474:MetaCyc 411:CAS no. 191:UniProt 150:Ensembl 93:Species 49:Aliases 7442:Portal 7384:Lyases 7060:ALOX15 7046:ALOX12 6895:Others 6819:MK-886 6735:DG-051 6683:2-TEDC 6671:15-LOX 6645:2-TEDC 6633:12-LOX 6622:MK-886 6617:MK-591 6607:AM-679 6602:AM-103 6516:BW-A4C 6506:2-TEDC 6476:Enzyme 6298:MK-571 6121:12-HHT 5536:Human 5533:(MeSH) 5510: 5481: 5446: 5411: 5382: 5361: 5351: 5318: 5289: 5260: 5225: 5215: 5172: 5137: 5130:279559 5127: 5084: 5049: 5042:279474 5039: 4996: 4986: 4943: 4908: 4879: 4869: 4844: 4805: 4710: 4702: 4666: 4656: 4617: 4607: 4565: 4555: 4516: 4508: 4473: 4465: 4445:Cancer 4403: 4362: 4352: 4313: 4217: 4209: 4174: 4126: 4116: 4077: 4069: 4034: 4024: 3985: 3977: 3936: 3891: 3881: 3842: 3834: 3816:Lipids 3799: 3789: 3750: 3740: 3701: 3691: 3646: 3636: 3575: 3565: 3524: 3516: 3474: 3466: 3424: 3414: 3372: 3326: 3316: 3285: 3275: 3233: 3225: 3215: 3176: 3168: 3133: 3126:507119 3123: 3084: 3048: 3038: 2992: 2948: 2938: 2896: 2858: 2848: 2809: 2799: 2768: 2718: 2685:R03058 2672:R01595 2656: 2604: 2556: 2508: 2501:286962 2498: 2417:gene, 2398:; and 2376:asthma 2313:asthma 2237:, and 2096:asthma 2087:eczema 2082:rashes 2077:asthma 1904:eczema 1899:rashes 1894:asthma 1802:acute 1697:, and 1615:ALOX15 1482:, and 1467:asthma 1461:, and 1418:, and 1416:5-HETE 1398:ALOX15 1354:5-HETE 1136:serine 976:5-HETE 744:, and 732:, and 607:enzyme 554:PubMed 536:Search 522:AmiGO 510:PDBsum 450:ExPASy 438:BRENDA 426:IntEnz 399:EC no. 341:search 339:PubMed 109:Entrez 7336:Types 7015:1.13) 6494:5-LOX 6437:CysLT 6374:CysLT 6201:CysLT 6187:CysLT 5770:PTGS2 5765:PTGS1 5545:ALOX5 5539:ALOX5 5218:41452 4989:55106 4708:S2CID 4514:S2CID 4471:S2CID 4424:[ 4215:S2CID 4075:S2CID 3983:S2CID 3840:S2CID 3522:S2CID 3472:S2CID 3231:S2CID 3174:S2CID 2431:ALOX5 2419:ALOX5 2415:ALOX5 2301:ALOX5 2285:ALOX5 2047:(see 1906:(see 1839:(see 1761:Alox5 1729:Alox5 1709:ALOX5 1705:cecum 1680:Alox5 1670:Alox5 1585:, or 1498:(see 1380:) by 1372:) by 1064:MGST2 843:Dicer 682:Egr-1 646:exons 638:ALOX5 611:ALOX5 597:, or 595:5-LOX 587:ALOX5 486:PRIAM 102:Mouse 97:Human 7428:list 7421:EC7 7415:list 7408:EC6 7402:list 7395:EC5 7389:list 7382:EC4 7376:list 7369:EC3 7363:list 7356:EC2 7350:list 7343:EC1 6593:FLAP 5867:HPGD 5602:heme 5508:PMID 5492:Gene 5479:PMID 5444:PMID 5409:PMID 5380:PMID 5359:PMID 5316:PMID 5300:Gene 5287:PMID 5258:PMID 5223:PMID 5170:PMID 5135:PMID 5082:PMID 5047:PMID 4994:PMID 4941:PMID 4906:PMID 4877:PMID 4867:ISBN 4842:PMID 4803:PMID 4700:PMID 4664:PMID 4615:PMID 4563:PMID 4541:1851 4506:PMID 4463:PMID 4401:PMID 4360:PMID 4311:PMID 4207:PMID 4172:PMID 4124:PMID 4067:PMID 4032:PMID 3975:PMID 3934:PMID 3889:PMID 3832:PMID 3797:PMID 3748:PMID 3699:PMID 3675:2014 3644:PMID 3573:PMID 3514:PMID 3464:PMID 3422:PMID 3370:PMID 3324:PMID 3283:PMID 3223:PMID 3166:PMID 3131:PMID 3082:PMID 3070:1736 3046:PMID 2990:PMID 2946:PMID 2924:1851 2894:PMID 2856:PMID 2807:PMID 2797:ISBN 2766:PMID 2716:PMID 2704:1854 2654:PMID 2642:1851 2602:PMID 2554:PMID 2506:PMID 2339:and 2241:are 2222:AKBA 2161:and 2058:and 1952:skin 1950:and 1874:and 1858:and 1502:and 1463:LTE4 1459:LTD4 1455:LTC4 1449:BLT2 1447:and 1445:BLT1 1412:LTB4 1394:LTE4 1390:LTD4 1378:LTC4 1370:LTB4 1366:LTA4 1209:(PLA 1156:Cdc2 1112:LTE4 1110:and 1108:LTD4 1012:LTA4 872:Grb2 839:COL1 789:mRNA 780:and 680:and 636:The 632:Gene 614:gene 603:heme 599:5-LO 566:NCBI 507:PDBe 462:KEGG 6862:LTD 6830:LTC 6798:LTC 6771:LTB 6709:LTA 6688:CDC 6660:CDC 6531:CDC 6098:BLT 5955:BLT 5941:BLT 5500:doi 5496:200 5469:doi 5434:doi 5430:272 5401:doi 5397:230 5349:PMC 5341:doi 5337:178 5308:doi 5304:138 5279:doi 5248:doi 5244:269 5213:PMC 5203:doi 5160:doi 5156:232 5125:PMC 5115:doi 5072:doi 5068:263 5037:PMC 5027:doi 4984:PMC 4974:doi 4931:doi 4927:266 4898:doi 4894:182 4859:doi 4834:doi 4830:161 4793:doi 4789:350 4692:doi 4654:PMC 4646:doi 4642:785 4605:PMC 4597:doi 4593:124 4553:PMC 4545:doi 4498:doi 4494:273 4453:doi 4449:117 4391:doi 4350:PMC 4342:doi 4338:101 4303:doi 4199:doi 4162:doi 4158:114 4114:PMC 4106:doi 4102:111 4059:doi 4022:PMC 4014:doi 3965:doi 3961:157 3924:doi 3879:PMC 3871:doi 3824:doi 3787:PMC 3779:doi 3775:196 3738:PMC 3730:doi 3689:PMC 3679:doi 3634:PMC 3626:doi 3563:PMC 3553:doi 3506:doi 3456:doi 3412:PMC 3404:doi 3362:doi 3314:PMC 3273:PMC 3265:doi 3261:171 3213:PMC 3205:doi 3158:doi 3121:PMC 3113:doi 3074:doi 3036:PMC 3028:doi 2980:doi 2936:PMC 2928:doi 2886:doi 2882:760 2846:PMC 2838:doi 2789:doi 2758:doi 2754:111 2708:doi 2646:doi 2594:doi 2544:doi 2540:114 2496:PMC 2486:doi 2258:). 1843:). 1641:,19 1637:,16 1633:,13 1629:,10 1577:,17 1573:,14 1569:,11 1541:,11 1525:,11 1506:). 1340:,14 1336:,11 1122:). 1098:,14 1094:,11 1062:2 ( 1050:,14 1046:,12 1042:,10 1026:,12 1006:,14 1002:,11 986:, 5 970:,14 966:,11 938:,14 934:,11 910:,14 906:,11 855:An 830:An 817:kDa 678:Sp1 668:or 622:EFA 542:PMC 498:PDB 350:n/a 345:n/a 332:n/a 327:n/a 312:n/a 293:n/a 269:n/a 250:n/a 227:n/a 180:n/a 163:n/a 139:n/a 122:n/a 71:OMA 7468:: 7013:EC 7007:: 5710:– 5706:: 5593:: 5589:, 5506:. 5494:. 5477:. 5465:51 5463:. 5459:. 5442:. 5428:. 5424:. 5407:. 5395:. 5374:. 5357:. 5347:. 5335:. 5331:. 5314:. 5302:. 5285:. 5275:50 5273:. 5256:. 5242:. 5238:. 5221:. 5211:. 5201:. 5191:92 5189:. 5185:. 5168:. 5154:. 5150:. 5133:. 5123:. 5113:. 5103:85 5101:. 5097:. 5080:. 5066:. 5062:. 5045:. 5035:. 5025:. 5015:85 5013:. 5009:. 4992:. 4982:. 4972:. 4962:87 4960:. 4956:. 4939:. 4925:. 4921:. 4904:. 4892:. 4875:. 4865:. 4840:. 4828:. 4801:. 4787:. 4783:. 4764:. 4746:. 4728:. 4706:. 4698:. 4688:68 4686:. 4662:. 4652:. 4640:. 4636:. 4613:. 4603:. 4591:. 4587:. 4575:^ 4561:. 4551:. 4539:. 4535:. 4512:. 4504:. 4492:. 4469:. 4461:. 4447:. 4443:. 4399:. 4387:45 4385:. 4381:. 4358:. 4348:. 4336:. 4332:. 4309:. 4299:64 4297:. 4235:. 4213:. 4205:. 4195:15 4193:. 4170:. 4156:. 4152:. 4136:^ 4122:. 4112:. 4100:. 4096:. 4073:. 4065:. 4055:45 4053:. 4030:. 4020:. 4010:16 4008:. 4004:. 3981:. 3973:. 3959:. 3955:. 3932:. 3920:71 3918:. 3914:. 3901:^ 3887:. 3877:. 3867:16 3865:. 3861:. 3838:. 3830:. 3820:26 3818:. 3795:. 3785:. 3773:. 3769:. 3746:. 3736:. 3724:. 3720:. 3697:. 3687:. 3673:. 3669:. 3642:. 3632:. 3622:83 3620:. 3616:. 3593:. 3571:. 3561:. 3547:. 3543:. 3520:. 3512:. 3502:27 3500:. 3496:. 3484:^ 3470:. 3462:. 3452:39 3450:. 3434:^ 3420:. 3410:. 3400:27 3398:. 3394:. 3382:^ 3368:. 3358:85 3356:. 3336:^ 3322:. 3308:. 3304:. 3281:. 3271:. 3259:. 3255:. 3243:^ 3229:. 3221:. 3211:. 3201:73 3199:. 3195:. 3172:. 3164:. 3154:65 3152:. 3129:. 3119:. 3109:97 3107:. 3103:. 3080:. 3068:. 3044:. 3034:. 3024:52 3022:. 3018:. 3002:^ 2988:. 2976:64 2974:. 2970:. 2958:^ 2944:. 2934:. 2922:. 2918:. 2906:^ 2892:. 2880:. 2868:^ 2854:. 2844:. 2834:23 2832:. 2828:. 2805:. 2795:. 2764:. 2752:. 2748:. 2728:^ 2714:. 2702:. 2652:. 2640:. 2614:^ 2600:. 2590:15 2588:. 2566:^ 2552:. 2538:. 2534:. 2518:^ 2504:. 2494:. 2484:. 2474:86 2472:. 2468:. 2400:3) 2384:2) 2382:; 2360:1) 2319:. 2233:, 2051:) 1920:b) 1916:a) 1910:). 1860:b) 1848:a) 1739:, 1691:, 1625:,7 1565:,8 1557:, 1537:,8 1521:,8 1478:, 1457:, 1414:, 1332:,8 1324:, 1296:sn 1292:sn 1286:sn 1276:sn 1271:sn 1198:sn 1180:d) 1172:c) 1160:b) 1154:, 1146:, 1142:, 1132:a) 1090:,9 1038:,8 1034:,6 998:,8 990:,6 962:,8 930:,8 918:,8 902:,8 862:A 848:A 823:A 756:, 740:, 728:, 724:, 720:, 716:, 712:, 708:, 696:, 593:, 589:, 524:/ 69:; 66:: 7444:: 7430:) 7426:( 7417:) 7413:( 7404:) 7400:( 7391:) 7387:( 7378:) 7374:( 7365:) 7361:( 7352:) 7348:( 7172:e 7165:t 7158:v 7058:/ 7044:/ 7034:: 7011:( 6997:e 6990:t 6983:v 6937:4 6864:4 6834:H 6832:4 6802:S 6800:4 6775:H 6773:4 6713:H 6711:4 6484:) 6480:( 6457:4 6439:E 6410:4 6402:4 6394:4 6376:2 6237:4 6229:4 6221:4 6203:1 6151:4 6143:4 6100:2 6006:4 5988:4 5980:4 5957:1 5931:) 5927:( 5901:e 5894:t 5887:v 5825:/ 5696:e 5689:t 5682:v 5579:e 5572:t 5565:v 5552:. 5514:. 5502:: 5485:. 5471:: 5450:. 5436:: 5415:. 5403:: 5386:. 5376:8 5365:. 5343:: 5322:. 5310:: 5293:. 5281:: 5264:. 5250:: 5229:. 5205:: 5197:: 5176:. 5162:: 5141:. 5117:: 5109:: 5088:. 5074:: 5053:. 5029:: 5021:: 5000:. 4976:: 4968:: 4947:. 4933:: 4912:. 4900:: 4883:. 4861:: 4848:. 4836:: 4809:. 4795:: 4768:. 4750:. 4732:. 4714:. 4694:: 4670:. 4648:: 4621:. 4599:: 4569:. 4547:: 4520:. 4500:: 4477:. 4455:: 4407:. 4393:: 4366:. 4344:: 4317:. 4305:: 4250:. 4221:. 4201:: 4178:. 4164:: 4130:. 4108:: 4081:. 4061:: 4038:. 4016:: 3989:. 3967:: 3940:. 3926:: 3895:. 3873:: 3846:. 3826:: 3803:. 3781:: 3754:. 3732:: 3726:7 3705:. 3681:: 3650:. 3628:: 3597:. 3579:. 3555:: 3549:7 3528:. 3508:: 3478:. 3458:: 3428:. 3406:: 3376:. 3364:: 3350:5 3346:4 3330:. 3310:3 3289:. 3267:: 3237:. 3207:: 3180:. 3160:: 3137:. 3115:: 3088:. 3076:: 3052:. 3030:: 2996:. 2982:: 2952:. 2930:: 2900:. 2888:: 2862:. 2840:: 2813:. 2791:: 2772:. 2760:: 2722:. 2710:: 2660:. 2648:: 2608:. 2596:: 2560:. 2546:: 2512:. 2488:: 2480:: 2370:/ 2329:S 2224:) 2013:) 1982:. 1928:S 1852:S 1810:) 1643:Z 1639:Z 1635:Z 1631:Z 1627:Z 1623:Z 1579:Z 1575:Z 1571:Z 1567:Z 1563:Z 1543:Z 1539:Z 1535:E 1531:S 1527:Z 1523:Z 1519:Z 1342:Z 1338:Z 1334:Z 1330:Z 1281:O 1251:2 1247:2 1243:2 1235:2 1231:2 1223:2 1219:2 1215:2 1211:2 1100:Z 1096:Z 1092:E 1088:E 1084:R 1080:S 1074:- 1070:- 1052:Z 1048:R 1044:E 1040:E 1036:Z 1032:S 1028:R 1024:S 1008:Z 1004:Z 1000:Z 996:E 992:S 988:S 980:S 972:Z 968:Z 964:Z 960:E 956:S 948:S 944:S 940:Z 936:Z 932:Z 928:E 924:S 920:Z 916:Z 912:Z 908:Z 904:Z 900:Z 896:2 878:. 209:a 205:n 73:: 20:)

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

Knowledge (XXG)

Arachidonate 5-lipoxygenase

Index